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1. Introduction 
 
 
1.1 Assessment of tumor textural heterogeneity in PET scans 
 
Since last three decades PET (positron emission tomography) is serving as the work 
horse in the diagnosis and management of oncological disorders. Since its introduction as a 
highly effective functional imaging technique PET has continually played its role in various 
aspects for example confirmation of diagnosis, tumor staging and re-staging, tumor efficacy 
assessment both during and after treatment and radiotherapy planning (Gallamini et al., 
2014).  Overtime there has been a continuous progress in the enhancement of PET use 
with the introduction of new radionuclides for imaging and software developments. One of 
such important technological development is the application of tumor textural heterogeneity 
in PET images. 
 
Different imaging modalities for example X-rays, ultrasonography, computerized 
tomography (CT), magnetic resonance imaging (MRI) and PET are applied for the 
assessment of appearance and spread of the lesions. These modalities can be used 
depending on the tumor type and the location of lesions. The interpretation of all these 
modalities is essentially visual. However, there are features within each image that cannot 
be apprehended by the naked eye. Furthermore, when images are analyzed in a more 
quantitative manner, standard region of interest analysis may provide a mean parameter 
value, e.g., Hounsfield unit (HU) on CT, signal intensity (SI) on MRI, or standardized uptake 
value (SUV) on PET, but does not typically describe the underlying spatial distribution 
(Davnall et al., 2012). 
 
Tumors are heterogeneous both on genetic and histopathological levels. Despite the 
fact that tumors usually originate from a single cell, human cancers frequently display 
substantial intra-tumor heterogeneity in virtually all distinguishable phenotypic features, 
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such as cellular morphology, gene expression (including the expression of cell surface 
markers and growth factor and hormonal receptors), metabolism, motility, and angiogenic, 
proliferative, immunogenic, and metastatic potential (Fidler and Hart, 1982; Dick, 2008; 
Nicolson, 1984; Heppner, 1984). A large number of cell divisions is required for genetic 
instability and thus highly malignant cell lines. It can be believed that there is presence of 
very diverse tumor cell clones in a tumor. The existence of tumoral heterogeneity at clonal 
level has been observed and documented for a variety of malignancies, including 
leukemias, breast, prostate, colon, brain, esophagus, head and neck, bladder, and 
gynecological carcinomas. This genetic heterogeneity translates into phenotypic 
heterogeneity evident as spatial variation with in the tumor. Tumors with high intratumoral 
heterogeneity have been shown to have poorer prognosis, which could be secondary 
to intrinsic aggressive biology or treatment resistance (Hockel et al., 1993, 1996; Yang et 
al., 2011).   Figure 1 shows some of the precursors for high tumoral heterogeneity. 
 
 
ill 1: Genetic precursors of high genetic heterogeneity (Hanahan D, Weinberg RA, 2011) 
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The identification of tumor heterogeneity in a tumor can be helpful in effective lesion 
characterization and therapy planning.  It is not possible to assess intratumoral 
heterogeneity with biopsy as biopsy is a probe into a very small area of tumor and cannot 
inform about the full extent of phenotypic and genetic variation within the tumor (Gerlinger 
et al., 2012). Therefore, a non-invasive imaging method for assessing the tumor 
heterogeneity is of utmost importance as this can help in selecting patients with poor 
prognosis and an attempt can be made in redesigning the treatment which is vital part of 
personalized therapy. Numerous studies with good outcomes have shown that 
measurement of tumor textural heterogeneity by PET can a quantifiable parameter and can 
be easily applied.  
 
 
ill 2: Assessment of textural heterogeneity (A). Whole-body 18F-FDG PET scan (B). Tumor 
segmentation (C). Voxel intensity resampling allowing (D). The extraction of different 
features (Tixier et al., 2011) 
 
 
1.2  Texture Analysis 
 
Texture analysis refers to a variety of mathematical methods that can be used to 
evaluate the intensity level and position of the pixels within an image, or a part of image, to 
derive so-called ‘texture features’ that provide a measure of intralesional 
heterogeneity (Castellano et al., 2004). Different methods have been applied, including 
statistical-, model-, and transform-based methods (Al-Kadi and Watson, 2008; Ganeshan et 
al., 2007; brown and Frayne, 2008; Gog et al., 2009; Sanghera et al., 2012; Craciunescu et 
al., 1999; Dettori and Semler, 2007; Al-Kadi, 2010). Statistical-based techniques have been 
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most commonly applied and describe the distribution and relationships of intensity-level 
values in the image. Three orders of parameters are described in statistical-based texture 
analysis (Craciunescu et al., 1999; Dettori and Semler, 2007; Al-Kadi, 2010).  
 
First-order statistics relate to intensity level frequency distribution within the region of 
interest, which can be obtained from the histogram of pixel intensities. It is dependent on a 
single pixel value rather than its interaction with neighboring pixels (Tuceryan and Jain, 
1998). First order statistics based on histogram analysis include intensity (mean, minimum 
and maximum), uniformity, skewness and kurtosis. Second-order statistics are co-
occurrence measurements calculated using spatial gray-level dependence matrices. These 
matrices determine how often a pixel of intensity i finds itself within a certain relationship to 
another pixel of intensity j. Second-order statistics based on a co-occurrence matrix 
(GLCM) include entropy, homogeneity, dissimilarity and correlation (Tuceryan and Jain, 
1998). Higher-order statistics are calculated using neighborhood gray-tone-difference 
matrices, which examine the spatial relationship among three or more pixels (Amadasun 
and King, 1989; Srinivasan and Shobha, 2008). This is calculated using the neighborhood 
gray-tone-difference matrix (NGTDM). Examples of higher-order statistics include contrast, 
coarseness and busyness.  
 
Numerous studies show the positive outcome of textural heterogeneity analysis. Several 
hundred published articles have investigated the beneficial information that can be 
extracted from the analysis of tumor heterogeneity. More than 70 percent of articles involve 
MR and ultrasonography. Since the last decade the interest in exploring tumor 
heterogeneity using PET has gained momentum and is being explored worldwide owing to 
a great role of PET in oncology. One such study was conducted by Bundschuh et al 
(Bundschuh et al., 2014). Aim of this study was to investigate the predictive and prognostic 
value of tumor heterogeneity assessed in FDG PET-CT in patients with colorectal cancer 
treated with neoadjuvant radiochemotherapy using histopathology as gold standard and 
clinical follow up. Assessment of tumor heterogeneity was performed using coefficient of 
variation (COV), skewness and kurtosis. For comparison, the conventional PET parameters 
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such as SUV (standard uptake value), tumor volume and maximum diameter were used. 
Results showed that COV showed best predictive capability for histopathologic response. 
COV in pre-therapeutic PET also showed significant prognostic capability for progression 
free survival. Similarly, in another study conducted by Pyka et al (Pyka et al., 2015) the 
objective was to investigate the predictive and prognostic value of the textural heterogeneity 
parameters in  FDG PET-CT before start of stereotactic radiotherapy in non-small cell lung 
carcinoma with long-time follow-up for comparison. In the results two parameters entropy 
and correlation showed the best predictive capability for local recurrence and also for 
predicting long term survival. 
 
We carried out this study as an effort to improving the diagnostic accuracy of PET-
CT by the use of textural heterogeneity parameters. The presented work comprises of three 
parts. In the first part we used textural heterogeneity parameters in the differentiation of 
pseudoprogression from real progression in high grade glioma patients using FET (flouro 
ethyl tyrosine) PET. In the second part of our study we studied the role of textural 
heterogeneity parameters for patient selection in 177Lu-PSMA (prostate specific membrane 
antigen) therapy via 68Ga-PSMA PET. In the third part of our study we studied the role of 
textural heterogeneity parameters for therapy response assessment and prognosis in 
prostate cancer patients undergoing 177Lu-PSMA therapy.  
 
1.3 Role of textural heterogeneity parameters in diagnosis of  
      pseudoprogression in high grade gliomas 
 
The objective of this study was to distinguish between true tumor progression and 
pseudoprogression in the patients of high grade glioma using textural heterogeneity 
parameters in FET-PET as compared to the conventional PET parameters. 
 
The management of high grade gliomas (HGG) is very complex. The standard 
options available for treatment include surgery followed by chemotherapy and radiotherapy. 
Numerous factors put a direct influence on the selection of appropriate treatment option. 
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These include age, performance status of patient, histological type of the tumor ad its 
grade. The gold standard for follow up us is magnetic resonance imaging (MRI) However, in 
numerous cases it becomes really difficult to differentiate between the treatment response 
and the tumor effect. However, this distinction is very essential for further planning of 
therapy. Different diagnostic methods being utilized to get best possible results including 
proton spectroscopy, dynamic imaging with contrast enhanced MRI and amino acid 
radiotracer imaging (Khan et al., 2016).  
 
Gliomas can be highly malignant tumors that originate from the glial cells or their 
precursors in the central nervous system. They comprise of the major chunk of all 
malignancies of the central nervous system. The current World Health Organization 
histologic classification system uses histopathologic changes of cellular atypia, mitotic 
activity, endothelial cell proliferation, and necrosis to classify gliomas as “low grade” 
(grades I and II) and “high grade” (grades III and IV) (Louis et al., 2007). Despite state-of-
the-art surgery, radiation therapy and chemotherapy, the prognosis of patients with high-
grade glioma is grim. In patients with the most aggressive and devastating form of high 
grade gliomas, glioblastoma, median overall survival is about 17 months. 
 
Pseudoprogression can be defined as new areas of enhancement or edema that do 
not arise from actual tumor progression, but from chemoradiotherapy related inflammation, 
which is likely because of increased vascular permeability (Brandsma et al., 2008). This 
phenomenon of pseudoprogression was recognized as early as 1979 (Hoffmann et al., 
1979). To this day pseudoprogression poses a great clinical challenge because its 
appearance at imaging is indistinguishable from that of true disease progression. Before the 
use of Temozolomide (TMZ) chemoradiation, only approximately 1% of patients treated 
with focal fractional radiotherapy alone would develop treatment-related imaging changes 
(Chaskis et al., 2009). However, with the current regimen, pseudoprogression been 
reported in up to 50% of patients, typically noted at the first follow-up MRI obtained within 
2–3 months after chemoradiation therapy (Taal et al., 2008). 
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Failure to identify pseudoprogression can lead to various negative outcomes directly 
affecting the morbidity and mortality of the patient. It can result in unnecessary surgical 
interventions or excessive chemotherapy. It can also result in premature termination of 
treatment. As pseudoprogression is a transient phenomenon occurring as a side effect of 
chemoradiation, it has the capability of spontaneous resolution. This spontaneous 
resolution can also give the false impression that therapy is effective. So, it is very essential 
to differentiate it from the actual tumor progression. On the other hand, successful 
differentiation of pseudoprogression from actual tumor progression can lead to an 
improvement in prognosis, possibly because of the increased likelihood of O6-
methylguanine-DNA-methyltransferase (MGMT) gene promoter methylation in this 
population (Gahramanov et al., 2014).  
 
In response to the accumulative evidence regarding the role of pseudoprogression in 
deciding treatment modifications, the Response Assessment in Neuro-Oncology (RANO) 
criteria provided an update in 2010 to account for the phenomenon of pseudoprogression 
(Wen et al., 2010). The RANO criteria specifies that, within the first 12 weeks after 
completion of radiotherapy, tumor progression can be established only if most of the new 
enhancement occurs outside the radiation field or if histologic confirmation of progression is 
obtained. However, a diagnostic dilemma remains for enlarging enhancement and 
peritumoural edema that occurs within the radiation field during the initial 12 weeks. Biopsy 
samples can sometimes reveal either obvious tumor growth or therapy-induced changes, 
but in many instances, even histologic assessment fails to resolve the dilemma because of 
sampling errors, inconclusive specimens with mixed treatment and tumor histologic 
findings, inter-observer variability, and inconsistent definitions of residual and recurrent 
disease (Melguizo-Gavilanes et al., 2015). 
 
Currently the diagnosis of pseudoprogression is built on increasing contrast 
enhancement on MRI. When an increasing contrast-enhancing lesion on MRI indicates 
pseudoprogression, the current gold standard is to perform follow-up MRIs to evaluate 
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changes in lesion size. Consequently, a diagnosis of pseudoprogression can only be made 
retrospectively based on follow-up MRI. It would be, however, advantageous for patient 
management if pseudoprogression could be identified at the earliest possible time point 
when the increasing contrast-enhancing lesions are detected for the first time. This is 
particularly important for patients with greatly increasing contrast-enhancing lesions and 
deteriorating clinical status. These patients might not be able to wait 4-8 weeks for a follow-
up MRI to decide whether secondary surgery or any other therapeutic adjustments are 
necessary. 
 
To make an effective and timely diagnosis of pseudoprogression different treatment 
modalities are being used, among them positron emission tomography is very effective. In 
cases of true progression there is increased radiotracer accumulation the lesions as 
compared to pseudoprogression. More important of these are the imaging techniques 
involving radiotracers other than conventional 18-flourodeoxygenase (FDG) PET as its 
application is limited owing to high glucose metabolic state of the normal brain tissue 
resulting in a decreased signal to noise ratio. FDG PET also shows an increased uptake in 
inflammatory cells which can hinder the diagnosis of actual tumor.  There is increased 
protein synthesis in brain tumors making amino acid radiotracers as an effective mode of 
imaging. In a study evaluating 72 patients with 11C–methionine PET, a threshold uptake 
index of 9 could distinguish between true tumor progression and pseudoprogression with 
83.5% sensitivity and 97% specificity (Skvortsova et al., 2014). A smaller study using 
PET imaging with the amino acid tracer O-2-18F-fluoroethyl-L-tyrosine and a cut-off value of 
2.3 demonstrated 100% sensitivity and 91% specificity in discriminating true tumor 
proliferation from pseudoprogression (Galldiks et al., 2014). In the recent years use of 18F-
FET PET has been increased a lot in brain tumor imaging. The rapid accumulation of FET 
in brain tissue is independent of blood brain barrier disruption as compared to MRI where 
contrast enhancement can cause reactive changes to blood brain barrier which can then 
mimic tumor progression. 
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In a study (Galldiks et al., 2015) the aim was to assess the clinical value of 18F-FET 
PET in the differentiation of pseudoprogression (PsP) and early tumor progression (EP) 
after radiochemotherapy of glioblastoma. A group of 22 glioblastoma patients with new 
contrast-enhancing lesions or lesions showing increased enhancement (>25 %) on 
standard MRI within the first 12 weeks after completion of radiochemotherapy with 
concomitant temozolomide (median 7 weeks) were additionally examined using amino 
acid PET with 18F-FET. Pseudoprogression was confirmed in 11 of the 22 patients. In 
patients with pseudoprogression, 18F-FET uptake was significantly lower than in patients 
with early tumor progression and presence of MGMT promoter methylation was 
significantly more frequent (P = 0.05). It was concluded that 18F-FET PET may facilitate 
the diagnosis of pseudoprogression following radiochemotherapy of glioblastoma. In 
another study (Rachinger et al., 2005) the objective was to analyze the diagnostic value of 
FET-PET and MRI in the detection of tumor recurrence in patients with glioma after 
radiotherapy, radiosurgery, or multimodal treatment. Results showed that Specificity of 
FET-PET was 92.9%, and sensitivity was 100% (in patients suspected of having recurrent 
tumor as revealed by MRI). Sensitivity of MRI was 93.5%, and specificity was 50% (P < 
0.05). It was concluded that for patients with gliomas undergoing multimodal treatment or 
various forms of irradiation, conventional follow-up with MRI is insufficient to distinguish 
between benign side effects of therapy and tumor recurrence. FET-PET is a powerful tool to 
improve the differential diagnosis in these patients. 
 
Similarly, role of tumor textural heterogeneity has been evaluated in various brain 
tumors including gliomas, but most of the times it has been based on MRI. In a recent study 
by (Liu et al., 2017) the aim was to assess the glioblastoma heterogeneity with MR imaging 
textures and to evaluate its impact on survival time. The results suggest that local and 
regional heterogeneity may play an important role in the survival stratification of patients 
with glioblastoma. The top 10 features included 7 run-length matrix and 3 co-occurrence 
matrix features, in which all 6 regional run-length matrix features emphasizing high gray-
levels ranked in the top 7. In another study by (Molina et al., 2016) the objective was to 
analyze three-dimensional (3D) heterogeneity measures of post-contrast pre-operative MR 
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images acquired with T1 weighted sequences of patients with glioblastoma as predictors of 
clinical outcome. Results showed that 4 of the 11 run length matrix features and 4 of the 5 
co-occurrence matrix features considered were robust predictors of survival. The median 
survival differences in the most significant cases were of over 6 months. It was concluded 
that heterogeneity measures computed on the post-contrast pre-operative T1 weighted MR 
images of patients with glioblastoma are predictors of survival. 
 
In the study we carried out, the aim was to distinguish between pseudoprogression 
and real tumor progression in high grade glioma patients using textural heterogeneity 
parameters. The heterogeneity parameters were assessed in FET-PET images. The 
purpose of the study was to enable an earlier diagnosis of pseudoprogression which can 
help in therapy planning and thus directly affecting the survival outcome of patients, as the 
delay in this diagnosis can cause over or under treatment of patients. Fourteen patients 
with high grade glioma and suspected of pseudoprogression underwent FET-PET imaging. 
A set of 19 conventional and textural FET-PET features were evaluated and subjected to 
unsupervised consensus clustering. The final diagnosis of true progression versus 
pseudoprogression was based on follow-up MRI using RANO criteria.  
 
1.4 Role of textural heterogeneity parameters in patient selection for 177Lu-      
      PSMA therapy 
   
The objective of this study was to assess predictive ability of tumor textural 
heterogeneity parameters from baseline 68Ga-PSMA PET prior to 177Lu-PSMA therapy in 
hormone refractory metastatic prostate cancer patients. 
 
In the European Union, prostate cancer is ranked first among the most frequently 
diagnosed cancer among men, with around 345,000 new cases estimated in 2012. Prostate 
cancer accounted for 24 per cent of all new cancers in the same year. For 2015 the 
estimated number of new prostate cancer cases was about 365,000 (Crocetti Emanuele, 
15 
 
2015). Prostate cancer tends to be highly aggressive and can lead to significant mortality by 
causing death of more than 250.000 men each year (Lozano et al., 2012). For many years 
there were few options for treatment of metastatic prostate cancer. The ones available 
usually involved the use of androgen deprivation agents. However, there is continuous 
development of new and more effective agents for tackling prostate cancer. It is under 
persistent surveillance worldwide by physicians and researchers and it is of utmost 
importance to devise new methods aiming for earlier diagnosis and optimum individualized 
therapy of prostate cancer.  
 
Among the ongoing advancements for the treatment of prostate cancer the 
possibilities involving Prostate Specific Membrane Antigen (PSMA) as an optimal diagnostic 
and therapeutic marker have gained momentum. PSMA is a type II membrane protein 
originally characterized by the murine monoclonal antibody (mAb) 7E11-C5.3 and is 
expressed in all forms of prostate tissue, including carcinoma (Ross et al., 2003; 
Horoszewicz et al., 1987). Significant overexpression is seen in metastatic, hormone 
refractory and poorly differentiated carcinomas. Studies have consistently demonstrated 
PSMA expression in all types of prostate tissue and increased PSMA expression in cancer 
tissue (Silver et al., 1997; Troyer et al., 1995; Chang et al., 2011 ). Bostwick and colleagues 
(Bostwick et al., 1998) described PSMA immunohistochemical expression in 184 prostate 
specimens examined, all of which had PSMA expression and demonstrated a correlation 
between this expression and severity of cancer. There was an increase in the percentage of 
PSMA staining from benign epithelial tissue (69.5% of cells positive) to high-grade prostatic 
intraepithelial neoplasia (77.9% of cells positive) to malignant cells (80.2% of cells positive). 
 
The five year survival rate of locally advanced prostate cancer is nearly 100%; 
however, the rate is significantly lower in the case of metastatic disease (31%) (Jemal et al., 
2010). Therefore, developing new strategies for diagnosis, imaging, and treatment of 
metastatic prostate cancer is of major importance. As discussed earlier prostate specific 
membrane antigen serves as an ideal target for therapy especially for metastatic disease. 
Radiolabeled ligands targeting PSMA have recently been the subject of numerous studies 
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showing high sensitivity and contrast in detecting recurrent prostate cancer and its 
metastases with remarkable detection rates (Afshar-Oromieh et al., 2013; Eiber et al., 
2015). Recent studies have also shown a high sensitivity of PSMA-targeted imaging in 
determining the local extent of disease before radical prostatectomy (Rahber et al., 2016; 
Eiber et al., 2016). Benesová et al (Benesová et al., 2015) introduced a high-affinity PSMA 
ligand (PSMA-617) that can be labeled with 68Ga or 177Lu and demonstrates superior tumor-
to-background uptake. 
 
In order for therapy to become effective it is very essential to be able to select 
patients who can benefit most from therapy. It can serve as a basis of personalized 
medicine. This optimal patient selection can help transform the treatment options for 
patients depending on their response. As earlier in the course of therapy the efficacy of the 
treatment is predicted the more beneficial is the outcome. One approach is trying to deduce 
information from the pre-therapy scan. This is of great importance because some valuable 
data can be obtained even before the start of therapy. Patient selection can be made and 
patients can be assigned in various groups based on predicted responsiveness to available 
treatment options. A lot of data is available on evaluation of pre-therapy scans. Different 
parameters have been used to extract useful information from pre-therapy scans. As our 
research is based on the role of tumor textural heterogeneity parameters, we paid 
emphasis to studies which involved the use of textural heterogeneity parameters for 
evaluation of pre-therapy scans for patient selection and response prediction.  
 
In a study by Eary JF et al. (Eary et al., 2008) the aim was to support the hypothesis 
that a new heterogeneity-analysis algorithm applied to 18F-FDG PET images of tumors in 
sarcoma patients is predictive of patient outcome. 18F-FDG PET images from 238 patients 
with sarcoma were analyzed using a new algorithm for heterogeneity analysis in tumor 18F-
FDG spatial distribution. Statistical analyses show that heterogeneity analysis is a strong 
independent predictor of patient outcome. Cheng NM et al. (Cheng et al., 2013) sought to 
investigate whether the textural features of pretreatment 18F-FDG PET-CT images can 
provide any additional prognostic information over TLG and clinical staging in patients with 
17 
 
advanced T-stage oropharyngeal squamous cell carcinoma (OPSCC). Study involved the 
retrospective analysis of pretreatment 18F-FDG PET-CT images of 70 patients. The textural 
features of pretreatment 18F-FDG PET-CT images were extracted from histogram analysis, 
normalized gray-level co-occurrence matrix and neighborhood gray-tone difference matrix. 
It was concluded that uniformity extracted from the normalized gray-level co-occurrence 
matrix represents an independent prognostic predictor in patients with advanced T-stage 
OPSCC. Similarly, in another study by Pyka T et al. (Pyka et al., 2015) evaluated the 
predictive value of textural heterogeneity parameters in pre-treatment FDG –PET scans for 
recurrence and prognosis in NSCLC patients receiving primary stereotactic radiation 
therapy (SBRT). Entropy (AUC 0.872) predicted local recurrence. In another very 
interesting study by Tixier F et al. (Tixier et al., 2011) aim  was to propose and evaluate 
new parameters obtained by textural analysis of baseline PET scans for the prediction of 
therapy response in esophageal cancer. Different image-derived indices obtained from the 
pretreatment PET tumor images included usual indices such as maximum SUV, peak SUV, 
and mean SUV and a total of 38 features  extracted from the 5 different textures. It was 
concluded that textural features of tumor metabolic distribution extracted from baseline 18F-
FDG PET images allowed for the best stratification of esophageal carcinoma patients in the 
context of therapy-response prediction. 
 
These studies show that textural heterogeneity parameters can play a role in 
outcome prediction and as it can be seen from the abovementioned studies, very useful 
information can be gained from pre-therapy scans only, hence resulting in earliest possible 
options for treatment modifications in order to get better response. However, there is no 
data available explaining the role of textural heterogeneity from baseline 68Ga-PSMA scans. 
PSMA is now being widely used as a therapeutic agent in the form of 177Lu-PSMA (it will be 
discussed in detail in the next part) and this therapy has a very good response rate. Still 
some recent studies found a non-responder rate of about 30% (no PSA decline) after 
radiopeptide therapy with 177Lu-PSMA ( Ferdinandus et al., 2017; Ahmadzadehfar et al., 
2017; Rahbar et al., 2016; Rahbar et al., 2017).  
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The objective of this current study was hence to assess the predictive ability of tumor 
textural heterogeneity parameters from baseline 68Ga-PSMA PET scan. Selected textural 
heterogeneity parameters had been previously widely used in different studies and showed 
a significant potential for depicting the outcome ( Pyka et al., 2015; Tixier et al., 2011; Dong 
et al., 2016; Dong et al., 2015). The predictive value of these parameters was compared to 
established clinical parameters (Prostate specific antigen (PSA), serum and bone alkaline 
phosphate, eastern cooperative oncology group (ECOG) criterion). The aim of the study 
was to help in patient selection prior to 177Lu-PSMA therapy in an order to enhance the 
efficacy of therapy for responders which were determined from the baseline scans.  
 
1.5 Role of Tumor Textural Heterogeneity in 68Ga-PSMA PET-CT for Therapy  
      Response Assessment and Prognosis in Prostate Cancer Patients 
 
The last part of our study comprised of the assessment of role played by tumor 
textural heterogeneity parameters in prostate cancer patients undergoing 177Lu-PSMA 
therapy for assessing the response to therapy and prognosis of the patients.  
 
Since last three to four years, special emphasis is being paid to treatment of 
hormone refractory prostate cancer with 177Lu-PSMA therapy. Several studies reported 
promising results for response rates and a favorable safety profile after radioligand therapy 
(RLT) with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer 
(mCRPC) (Ahmadzadehfar et al., 2015; Kratochwil et al., 2016: Rahbar et al., 2016a, 
2016b; Ahmadzadehfar et al., 2016). In order to further strengthen these results, a 
retrospective multicenter study was initiated by the German Society of Nuclear Medicine in 
July 2015 (Rahbar et al., 2017). Twelve therapy centers retrospectively collected and 
pooled data on safety and efficacy of 177Lu-PSMA-617 RLT. This retrospective multicenter 
study aimed at analyzing the optimal dose and number of therapy cycles and predictors of 
response in more detail. This study demonstrated the favorable safety and efficacy of 177Lu-
PSMA-617 RLT in a large number of mCRPC patients and stated that 177Lu-PSMA-617 
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RLT might exceed the performance of other third-line systemic therapies reported in the 
literature. In the light of published data it could be deduced that radioligand therapy (RLT) 
with Lu-177 PSMA is effective and had a low toxicity profile ( Kratochwil et al., 2016). It was 
also observed that up to 30% of patients did not show prostate specific antigen (PSA) 
decline in response to RLT ( Kratochwil et al., 2016; Zechmann et al., 2014). 
  
  
ill. 3 Results of German multicenter study investigating 177Lu-PSMA-617 radioligand 
therapy in advanced prostate cancer patients (Rahbar et al., 2017) 
 
The therapy showed good response rate but in order to improve the efficacy of 
treatment for non-responsive patients, it is essential to devise some techniques which can 
help in better assessment of individual patient behavior. In our study, we aimed to analyze 
the role of textural heterogeneity parameters for therapy response assessment. Textural 
heterogeneity parameters have been used several times to assess the response of a tumor 
to therapy. In the study performed by Bundschuh et al. (Bundschuh et al., 2014) the 
objective was to analyze the capability of textural inhomogeneity markers on PET to predict 
histopathologic therapy response and outcome in patients with locally advanced rectum 
carcinoma treated with neoadjuvant radiation chemotherapy. Twenty-seven patients 
underwent 18F-FDG PET-CT before, 2 week after the start, and 4 week after the completion 
of neoadjuvant chemoradiotherapy. Convention PET parameters and tumor textural 
heterogeneity parameters were assessed in each scan. The results showed that a textural 
heterogeneity parameter COV (coefficient of variation) had statistically significant capability 
64 %: PSA-decrease 
31 %: PSA-decrease >50% 
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to assess histopathologic response early in therapy (sensitivity, 68%; specificity, 88%) and 
after therapy (79% and 88%, respectively). It was concluded that tumor heterogeneity 
assessed by the COV, being superior to the investigated conventional parameters, is an 
important predictive factor in patients with rectal cancer. Furthermore, it can provide 
prognostic information. Therefore, its application is an important step for personalized 
treatment of rectal cancer. Similarly,  Lapa C et al. analyzed in a study (Lapa et al., 2015) 
the potential of somatostatin receptor subtype II (SSTR)  PET to assess intraindividual 
tumor heterogeneity and thereby treatment response prior to peptide receptor radionuclide 
therapy  (PRRT). 12 patients with progressive radioiodine-refractory differentiated thyroid 
cancer were enrolled in the study. Conventional PET parameters and heterogeneity 
parameters were analyzed regarding their potential to predict progression-free (PFS, mean, 
221 days) and overall survival (OS, mean, 450 days). In patient-based analysis, all 
conventional parameters failed to predict PFS. Several textural parameters showed a 
significant capability to assess PFS. Thereby, "Grey level non uniformity" had the highest 
area under the curve (AUC, 0.93) in Receiver operating characteristics analysis followed by 
"Contrast" (AUC, 0.89). In lesion-based analysis, only "Entropy" revealed potential to 
evaluate disease progression. It was concluded that tumor textural heterogeneity seems to 
be a predictor of response to PRRT in patients with iodine-refractory 
differentiated/advanced medullary thyroid cancer and outperforms conventional PET 
parameters like standardized uptake value. 
 
The purpose of our study was to investigate the role of tumor heterogeneity in the 
assessment of therapy response on pre therapeutic (baseline) 68Ga-PSMA PET, as well as 
to monitor changes during the course of 177Lu-PSMA therapy by analyzing the mid-therapy 
and post-therapy scans as well. Every patient went under three 177Lu-PSMA therapies. 
Conventional and textural parameters were thoroughly analyzed in all PET scans. The gold 
standard was the serum PSA level. The changes in serum PSA level correlate with overall 
survival in castration resistant metastatic prostate cancer at showed by a recent study 
(Ahmadzadehfar et al., 2017). In addition to evaluating the predictive value of tumor 
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heterogeneity, we also analyzed the prognostic value for disease progression and overall 
survival. 
 
In the nutshell, our study aimed at the improvement in specificity of PET signals by 
the analysis of tumor textural heterogeneity parameters. This was performed in an effort to 
enhance the diagnostic accuracy of PET scans. In many instances the conventional PET 
parameters e.g. SUV, tumor volume are not able to give optimal information. Textural 
heterogeneity parameters are proving to be a better alternative for assessment. As seen 
from a large number of studies textural heterogeneity parameters are fast establishing their 
role in many aspects of diagnostic and therapeutic nuclear medicine. They are being widely 
used to predict response from baseline scans. This is of great importance, because useful 
analysis in baseline scans can give earliest possible insights into tumor behavior and 
therapy response prediction. It can help in selection of patients who can benefit from 
treatment and can also help to modify the therapy for otherwise nonresponsive patients 
thus not only improving the efficacy of therapy but also decreasing the disease burden of 
patient. Similarly, role of heterogeneity parameters is also seen in scans over the course of 
therapy to predict the prognosis and survival outcome of patients. They can also help 
distinguish pathology from reactive changes much more effectively than conventional 
parameters. All this has been discussed in abovementioned and many other studies. 
 
Role of textural heterogeneity parameters in FET-PET to distinguish 
pseudoprogression in high grade gliomas and their importance in PSMA therapy is the 
subject of our study. These scenarios have not been explored before and our study showed 
some very good outcomes which will be discussed in detail in the following sections.  
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2. Materials and Methods 
 
As our study has been divided into three parts the material and methods will be discussed 
in accordance. 
 
2.1 Role of textural heterogeneity parameters in diagnosis of     
       pseudoprogression in high grade gliomas 
 
2.1.1 Patient selection 
 
 
For this retrospective analysis, the patient files of the Division of Clinical Neuro-
oncology were searched for histologically confirmed high-grade glioma (HGG) patients 
meeting the following characteristics:  
 
(1) Patients experiencing increasing contrast-enhancing lesions on MRI (+25% in two 
perpendicular diameters) and/or any new lesion according to RANO (Wen et al., 
2010) (minimum lesion size >10 mm) more than 4 weeks after the end of 
radiotherapy,  
(2) Patients having a routine FET-PET following detection of increasing contrast-
enhancing lesions,  
(3) After initial MRI and FET-PET, a further contrast-enhanced MRI ensued at least 4 
weeks later without change of therapy. O-6-methylguanine-DNA methyltransferase 
(MGMT) promoter methylation status was tested using pyrosequencing (Mikeska et 
al., 2007). 
 
2.1.2 PET Imaging with 18F-FET  
Data were acquired with a Biograph Sensation 2 PET-computer tomography (PET-
CT) scanner (Siemens Medical Solutions). The axial and transverse fields of view were 
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16.2 and 58.5cm respectively. The transverse resolution of the scanner was about 6.5mm, 
whereas the axial resolution was 6.0mm, both at a radius of 10mm. The computer 
tomography (CT) component was a 2-slice spiral CT scanner. About 60 minutes after the 
intravenous injection of approximately 200 MBq of FET, the patient was placed in the 
scanner. Low dose CT of the head (caudocranial) was performed followed by the PET scan 
of the same area in a single bed position. The CT data were reconstructed in 512 x 512 
pixel matrices. PET data was reconstructed into 256 x 256 matrices using the iterative 
attenuation-weighted ordered subset algorithm implemented by the manufacturer using 4 
iterations and 16 subsets. Attenuation and scatter correction was performed using the CT 
data. Final voxel size was 5.3mm x 5.3mm x 5mm. All patients gave written and informed 
consent to the imaging procedure. 
 
2.1.3 PET Data Analysis 
 
Image data were transferred to an Interview Fusion Workstation (Mediso Medical 
Imaging System, Budapest, Hungary). Firstly, co-registration between PET and CT images 
was performed. Tumor volume was manually delineated on PET images. For background 
assessment 5 ROIs with a fixed diameter of 15mm were placed on normally appearing 
cortex area, 2 on the frontal lobe, 2 on the occipital lobe and 1 on the contralateral region to 
the tumor. A mean value was then calculated for these ROIs. In addition, a semiautomatic 
segmentation in PET was performed based on background activity for which tumor 
delineation cutoff was taken as 1.6 times the mean value of background ROIs. 
 
 For assessment of tumor uptake heterogeneity additional 13 textural heterogeneity 
PET parameters were estimated, namely, Coefficient of Variation (COV), Entropy, 
Correlation, Contrast, Size-zone Variability (Size variation), Intensity Variability (Intensity 
variation), Morphologic Volume of the Lesion (Volume), Coarseness, Complexity, Short 
Zone Emphasis (Short Zone Emphasis), Long Zone Emphasis (Long zone Emphasis), 
Zone Percentage, Short Run Emphasis (Short Run Emphasis), and Long Run Emphasis 
(Long Run Emphasis).  
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PET Feature Explanation 
Correlation 
A measure of continuous areas of same or similar voxel values in an 
image.  An image with high correlation values is usually associated 
with large areas of similar uptake intensities. 
Coarseness A measure of the intensity differences throughout the image. 
COV 
A normalized measure of dispersion of a frequency distribution 
(standard deviation divided by the mean value of the activity 
concentration in the tumor volume). 
Contrast 
A measure of local variations present in the image. A high contrast 
value indicates a high degree of local variation. 
Complexity Measures the uniformity of patterns versus rate of change in an image. 
Entropy 
Measures randomness of distribution, e.g. a homogenous matrix 
demonstrates low entropy. 
Size Variation 
Measures the difference of the grey value when going to the next 
voxel. It is high when the intensity changes very often between single 
voxels. 
Intensity 
Variation 
The intensity variation describes the variation of the intensity of 
different substructures. 
Short Run 
Emphasis 
Measure of consecutive pixels which have the same gray level intensity 
along a specific linear orientation. Fine textures tend to contain more 
short runs with similar gray level intensities. 
Long Run 
Emphasis 
Measure of consecutive pixels which have the same gray level intensity 
along a specific linear orientation. Coarse textures have more long runs 
with significantly different gray level intensities 
Short Zone 
Emphasis 
Measures the distribution of short zones as the difference of the grey 
value when going to the next voxel. It is high when the intensity 
changes very often between single voxels. 
Long Zone 
Emphasis 
Measures the distribution of long zones as the difference of the grey 
value when going to the next voxel. 
Zone 
Percentage Measures the percentage of zones of a given size. 
SUV Mean A measure of mean radiotracer accumulation in tumor lesions. 
SUV Max A measure of maximum radiotracer accumulation in tumor lesions. 
TNR Mean 
Mean tracer uptake in the tumor divided by that in normally appearing 
brain tissue. 
TNR Max 
Maximal tracer uptake in the tumor divided by that in normally 
appearing brain tissue. 
TLG The total lesion volume and its metabolic activity 
Volume The total lesion volume 
 
Table 1: Overview of textural heterogeneity parameters 
25 
 
All parameters were assessed in 3-dimensional volumes. In addition, the following 6 
conventional PET parameters were evaluated: mean SUV (Mean), maximum SUV (Max), 
Total Lesion Glycolysis (TLG), mean tumor to background ratios (TNRmean) and maximum 
tumor to background ratios (TNRmax). Their overview is shown in table 1. 
 
2.1.4 Diagnosis of True Progression 
 
The diagnosis of tumor progression was made when progressive contrast-enhancing 
lesions according to RANO criteria (Wen et al., 2010) were noted on initial MRI and when 
further progression of contrast-enhancement ensued on a follow-up MRI at least 4 weeks 
later. By contrast, the diagnosis of pseudoprogression was applied when the follow-up MRI 
showed stabilization or regression of the contrast-enhancing lesions, provided that neither 
clinical worsening nor change in treatment ensued in the interim. In all patients, MRI scan 
analysis was carried out by an experienced neuroradiologist and another independent 
investigator. 
 
In the event of true progression, progression-free survival (PFS) was defined as the 
time elapsed between the date of the true tumor progression (retrospectively defined as the 
date of the initial MRI conducted immediately before PET) and the date of the subsequent 
progression defined by MRI. In the event of pseudoprogression, PFS was defined as the 
time between the date of initial MRI conducted immediately before PET and the date of 
subsequent MRI defining progression. 
 
2.1.5 Subtype discovery 
 
Unsupervised consensus clustering was used for class discovery to uncover groups 
of items sharing FET-PET characteristics. Consensus clustering is a class discovery 
technique for the detection of unknown possible clusters consisting of items with similar 
intrinsic features (Wilkerson and Hayes, 2010). Being distinct from conventional clustering 
methods, it provides quantitative evidence to determine the number and membership of 
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clusters. To apply this method on our dataset, we first standardized FET-PET features to 
obtain z-scores. This was followed by subsampling 80% of items and PET features 10 000 
times and partitioning each subsample up into k=7 groups by the agglomerative hierarchical 
clustering algorithm using Pearson correlation distance. For each k, a consensus matrix 
was filled with consensus values, defined as the proportion of clustering repetitions in which 
two items are classified together. To determine the optimal number of k, we drew upon 
empirical cumulative distribution function (CDF) plots to find the k at which the distribution 
reached an approximate maximum, indicating a maximum stability. To validate the so 
obtained optimal number of clusters, we applied the proportion of ambiguous clustering 
(PAC) method (Wilkerson and Hayes, 2010). 
 
To identify a minimal subset of PET features that succinctly characterizes each 
cluster we used the nearest shrunken centroids method called predictive analysis of 
microarrays (PAM) (Wilkerson and Hayes, 2010). To this end, we used 10-fold cross-
validation to determine the amount of shrinkage at which the error rate was minimized. 
 
2.1.6 Statistical analysis 
 
To assess cluster stability in our unsupervised analysis, along with performing 
consensus clustering over 10 000 iterations we used the CDF and CDF progression graphs 
to detect the optimal number of clusters. Furthermore, we relied on PAC to confirm our 
choice. To compare clinical and molecular data across clusters, we used the Kruskal-Wallis 
test for continuous variables and the Fisher’s exact test for categorical variables. Moreover, 
logistic regression and Fisher’s exact test for 2 x 2 contingency tables were performed to 
assess the association of pseudoprogression with cluster assignments. A p-value below 5% 
was considered significant. Statistical analysis was carried out using Stata (release 14.0; 
StataCorp LP) and R Statistical Software (version 3.2.4). 
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2.2 Role of textural heterogeneity parameters in patient selection for 177Lu- 
       PSMA therapy 
 
2.2.1 Patient selection 
 
70 patients with histologically proven prostate cancer were retrospectively included 
in this study. Clinical data was collected from November 2014 to April 2016. All patients 
were planned to undergo 177Lu-PSMA-617 (abbreviated as 177Lu-PSMA in this study) 
radioligand therapy. Average age of patients was 71.46 years. Inclusion criteria for this 
retrospective analysis were progressive metastatic castration-resistant prostate cancer 
(mCRPC) patients.  Patients experienced progression under next-generation androgen-
deprivation therapy (e.g., abiraterone, enzalutamide) or first- or second-line chemotherapy 
(e.g., docetaxel, cabazitaxel) or were not eligible for chemotherapy. All patients eligible 
for 223Ra received this treatment before undergoing 177Lu-PSMA-617 radioligand therapy. 
39 patients had prior chemotherapy. 16 patients had been treated previously with 223Ra, 
while 27 patients had previous external beam radiation therapy (EBRT). 
 
2.2.2 68Ga-PSMA Scan 
 
A 68Ga-PSMA-617 (abbreviated in this study as 68Ga-PSMA) PET scan was 
performed for every patient. Each patient underwent 68Ga-PSMA scan before therapy with 
177Lu-PSMA termed as the baseline scan. The objectives of the baseline scan included 
staging and therapy planning. After the baseline scan patients underwent 177Lu-PSMA 
radioligand therapy. Renal function of every patient was analyzed prior to therapy with 
99mTc-MAG3 renal scintigraphy. Patient characteristics are shown in table 2. 
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Characteristic Data 
Age 71.46 years (48-88years) 
Site of metastasis: 
Bone 70 (100%) 
Lymph node 33 (47.1%) 
Other (liver, prostate) 15 (21.4 %) 
Previous therapy of mCRPC: 
Androgen deprivation therapy 70 (100%) 
Chemotherapy 39 (55.7%) 
223Ra 16 (22.8%) 
EBRT to bone 27 (38.5%) 
 
Table 2: Patient characteristics 
 
Data were acquired with a Biograph Sensation 2 PET/computer tomography 
(PET/CT) scanner (Siemens Medical Solutions). The axial and transverse fields of view 
were 16.2 and 58.5cm respectively. The transverse resolution of the scanner was about 
6.5mm, whereas the axial resolution was 6.0mm, both at a radius of 10mm. The computer 
tomography (CT) component was a 2-slice spiral CT scanner. About 73 minutes (range 50-
90 minutes) after the intravenous injection of approximately 131.3 MBq (range 98.8 to 174.8 
MBq) of 68Ga-PSMA, the patient was placed in the scanner. Low dose CT from the head to 
mid-thighs was performed followed by the PET scan of the same area in 6-7 bed positions, 
each for 3-4 minutes depending on the body weight of the patient. The CT data were 
reconstructed in 512 x 512 pixel matrices. PET data was reconstructed into 128 x 128 
matrices in axial, coronal and sagittal planes using the iterative attenuation-weighted 
ordered subset algorithm implemented by the manufacturer using 4 iterations and 16 
subsets. Attenuation and scatter correction was performed using the CT data. Final voxel 
size was 5.3mm x 5.3mm x 5mm. All patients gave written and informed consent to the 
imaging procedure. All patient record and information was anonymized before analysis. 
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ill. 4: ROIs for analysis of bone and lymph node lesions 
 
2.2.3 PET Data Analysis 
 
Image data were transferred to an Interview Fusion Workstation (Mediso Medical 
Imaging System, Budapest, Hungary). Firstly, co-registration between PET and CT images 
was performed. Tumor volume was manually delineated on PET images (Figure 1) with a 
standard uptake value (SUV) threshold (Fendler, 2017; Mathieu, 2015). All the 70 patients 
had bone metastasis. Thirty three patients had lymph node metastasis along with bone 
metastasis. Fifteen patients had additional liver and/or prostate lesions. Three VOIs each 
for bone and lymph node lesions were delineated manually. Other lesions were also 
delineated if present in liver and prostate. Parameters to be evaluated were measured in 
these VOIs. A total of 328 VOIs were delineated. Mean volume of the lesions was 32.9 cm3 
(range 7.8 cm3 to 82.3 cm3). For each patient three bone lesions were marked. Similarly, 
three lymph node and other (liver and prostate) lesions were delineated where applicable. 
For final analysis a mean value of every included parameter was determined.   
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2.2.4 Analysis of tumor textural heterogeneity 
 
Tumor textural heterogeneity was assessed by extraction of local and global textural 
features from uptake histogram analysis and normalized gray-level co-occurrence matrix 
(NGLCM) respectively (Dong et al., 2016). The selected heterogeneity parameters were 
COV, entropy, homogeneity, contrast and size variation (Table 3). The selected parameters 
have been used widely in numerous PET studies and showed a statistically significant 
ability to depict the role of textural heterogeneity for analysis of tumor behavior (Dong et al., 
2016; Eary et al., 2008; Cheng et al., 2013; Tixier et al., 2011; Pyka et al., 2015; Bundschuh 
et al., 2014; Divrik et al., 2012; Dong et al., 2015). SUV histogram analysis was used to 
calculate coefficient of variation (COV) (Chicklore et al., 2013; Tixier et al., 2012). Rest of 
the parameters, entropy, homogeneity, contrast and size variation were calculated from 
NGLCM contained three dimensional gray-level information (Chicklore et al., 2013; Tixier et 
al., 2012). For comparison purpose SUV as a conventional PET parameter was also 
analyzed. 
 
2.2.5 Treatment response 
 
After the baseline scan all patients underwent 177Lu-PSMA therapy. The decision 
for 177Lu-PSMA radioligand therapy was made by the local interdisciplinary tumor board at 
each therapy center. The protocol followed for therapy has already been explained in detail 
by rhaber et all (Rahbar et al., 2017). The parameters used to assess the response to 
177Lu-PSMA therapy were pre and post therapy changes in levels of PSA (prostate specific 
antigen), serum and bone alkaline phosphate and Eastern Cooperative Oncology Group 
(ECOG) criterion. Time difference between pre and post therapy levels was 7.1 weeks 
(average 6-8 weeks). 
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Parameter Order Description 
COV 1st 
A normalized measure of dispersion of a frequency distribution 
(standard deviation divided by the mean value of the activity 
concentration in the tumor volume). 
Entropy 2nd 
Measures randomness of distribution, e.g. a homogenous matrix 
demonstrates low entropy. 
Homogeneity 2nd 
A measure for continuous areas of same or similar voxel values in 
an image or voxel of interest (VOI). 
Contrast 2nd 
A measure of local variations present in the image. A high contrast 
value indicates a high degree of local variation. 
Size Variation 3rd 
Measures the difference of the grey value when going to the next 
voxel. It is high when the intensity changes very often between 
single voxels. 
 
Table 3: Overview of textural heterogeneity parameters 
 
2.2.6 Statistical Analysis 
 
The statistical analysis was performed using SPSS (version 22, IBM). To evaluate 
the correlation between conventional and textural heterogeneity parameters and changes in 
pre and post therapy clinical parameters Spearman correlation was used. Statistical tests 
were conducted at a two-sided level of significance as p < 0.05 
 
Receiver-operating-characteristics (ROC) analysis was also performed using 
MedCalc software (version 12.3.0.0; MedCalc). ROC analysis was performed to estimate 
the optimal cutoff value of the correlating parameters for response assessment. For this 
purpose, the Youden index was used to maximize the sum of sensitivity and specificity 
(Youden, 1950). The area under the curve (AUC) was calculated for each parameter using 
the nonparametric method developed by Hanley and McNeil (Hanley and McNeil, 1982) 
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representing the overall predictive or prognostic performance. For AUCs, exact binominal 
confidence intervals were calculated (95% confidence level), indicating the statistical 
significance of predictive capability if the critical value of 0.5 is not included. 
 
2.3 Role of tumor textural heterogeneity in 68Ga-PSMA PET-CT for therapy  
      response assessment and prognosis in prostate cancer patients 
 
2.3.1 Patient selection 
 
50 patients with histologically proven prostate cancer were retrospectively included 
in this study. All patients were planned to undergo 177Lu-PSMA-617 (abbreviated as 177Lu-
PSMA in this study) radioligand therapy. Clinical data was collected from November 2015 to 
April 2017. Average age of patients was 70.3 years.  
 
Characteristic Data 
Age 70.3 years (51-88years) 
Site of metastasis: 
Bone 50 (100%) 
Lymph node 22 (44 %) 
Other (liver, prostate) 7 (14 %) 
Previous therapy of mCRPC: 
Androgen deprivation therapy 50 (100%) 
Chemotherapy 26 (52.0%) 
223Ra 09 (18 %) 
EBRT to bone 18 (36 %) 
 
Table 4: Patient characteristics 
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Inclusion criteria for this retrospective analysis were progressive metastatic 
castration-resistant prostate cancer (mCRPC) patients.  Patients experienced progression 
under next-generation androgen-deprivation therapy (e.g., abiraterone, enzalutamide) or 
first- or second-line chemotherapy (e.g., docetaxel, cabazitaxel) or were not eligible for 
chemotherapy. All patients eligible for 223Ra received this treatment before 
undergoing 177Lu-PSMA-617 radioligand therapy. 26 patients had prior chemotherapy. 09 
patients had been treated previously with 223Ra, while 18 patients had previous EBRT. All 
patients were refractory to hormone therapy. 
 
2.3.2 68Ga-PSMA Scan:  
 
Three 68Ga-PSMA-617 (abbreviated in this study as 68Ga-PSMA) PET scans were 
performed for every patient. Each patient underwent a baseline 68Ga-PSMA scan before 
therapy with 177Lu-PSMA termed as the pre-therapy scan. After the baseline scan patients 
underwent first 177Lu-PSMA therapy. Renal function of every patient was analyzed prior to 
therapy with 99mTC- MAG3 renal scintigraphy. A post therapy 68Ga-PSMA scan was 
performed 6-8 weeks after the first therapy (average 7.6 weeks). This scan was termed as 
mid-therapy scan. After the mid-therapy scan two more PSMA therapies were given to 
every patient with an interval of 6-10 weeks (average 7.4 weeks). After completion of three 
therapies another 68Ga-PSMA scan was performed labeled as post-therapy scan. 
 
Data were acquired with a Biograph Sensation 2 PET-computer tomography (PET-
CT) scanner (Siemens Medical Solutions). The axial and transverse fields of view were 
16.2 and 58.5cm respectively. The transverse resolution of the scanner was about 6.5mm, 
whereas the axial resolution was 6.0mm, both at a radius of 10mm. The computer 
tomography (CT) component was a 2-slice spiral CT scanner. About 73 minutes (range 50-
90 minutes) after the intravenous injection of approximately 131.3 MBq (range 98.8 to 174.8 
MBq) of 68Ga-PSMA, the patient was placed in the scanner. Low dose CT from the head to 
mid-thighs was performed followed by the PET scan of the same area in 6-7 bed positions, 
each for 3-4 minutes depending on the body weight of the patient. The CT data were 
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reconstructed in 512 x 512 pixel matrices. PET data was reconstructed into 128 x 128 
matrices in axial, coronal and sagittal planes using the iterative attenuation-weighted 
ordered subset algorithm implemented by the manufacturer using 4 iterations and 16 
subsets. Attenuation and scatter correction was performed using the CT data. Final voxel 
size was 5.3mm x 5.3mm x 5mm. All patients gave written and informed consent to the 
imaging procedure. All patient record and information was anonymized before analysis. 
Same protocol was followed for all three scan performed per patient. 
  
2.3.3 PET Data Analysis 
 
Image data were transferred to an Interview Fusion Workstation (Mediso Medical 
Imaging System, Budapest, Hungary). Firstly, co-registration between PET and CT images 
was performed. Tumor volume was manually delineated on PET images. Tumor volume 
was manually delineated on PET images (Figure 1) with a standard uptake value (SUV) 
threshold (Fendler, 2017; Mathieu, 2015).). All the 50 patients had bone metastasis. Twenty 
two patients had lymph node metastasis along with bone metastasis. Seven patients had 
additional liver and/or prostate lesions. Three VOIs each for bone and lymph node lesions 
were delineated. Other lesions were also delineated if present in liver and prostate. 
Parameters to be evaluated were measured in these VOIs. A total of 260 VOIs were 
delineated. Mean volume of the lesions was 36.4 cm3 (range 8.2 cm3 to 82.3 cm3). For each 
patient three bone lesions were marked. Similarly, three lymph node and other (liver and 
prostate) lesions were delineated where applicable. For final analysis a mean value of 
every included parameter was determined.   
 
2.3.4 Analysis of tumor textural heterogeneity 
 
Tumor textural heterogeneity was assessed by extraction of local and global textural 
features from uptake histogram analysis and normalized gray-level co-occurrence matrix 
(NGLCM) respectively (Dong et al., 2016). The selected heterogeneity parameters were 
COV, entropy, homogeneity, contrast and intensity variation (Table 5).  
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Parameter Order Description 
COV 1st 
A normalized measure of dispersion of a frequency distribution 
(standard deviation divided by the mean value of the activity 
concentration in the tumor volume). 
Entropy 2nd 
Measures randomness of distribution, e.g. a homogenous matrix 
demonstrates low entropy. 
Homogeneity 2nd 
A measure for continuous areas of same or similar voxel values in 
an image or voxel of interest (VOI). 
Contrast 2nd 
A measure of local variations present in the image. A high contrast 
value indicates a high degree of local variation. 
Intensity 
Variation 
2nd 
The intensity variation describes the variation of the intensity of 
different substructures. 
 
Table 5: Overview of textural parameters 
 
The selected parameters have been used widely in numerous PET studies and 
showed a statistically significant ability to depict the role of textural heterogeneity for 
analysis of tumor behavior (Dong et al., 2016; Eary et al., 2008; Cheng et al., 2013; Tixier et 
al., 2011; Pyka et al., 2015; Bundschuh et al., 2014; Divrik et al., 2012; Dong et al., 2015). 
SUV histogram analysis was used to calculate coefficient of variation (COV) (Chicklore et 
al., 2013; Tixier et al., 2012). Rest of the parameters, entropy, homogeneity, contrast and 
intensity variation were calculated from NGLCM contained three dimensional gray-level 
information (Chicklore et al., 2013; Tixier et al., 2012). Intensity variation was also included 
due to its close approximation with entropy (measure of randomness of intensity values in 
an image (Alobaidli et al., 2014)) which is usually the determining feature in numerous 
studies. For comparison purpose SUV as a conventional PET parameter was also 
analyzed. 
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2.3.5 Treatment response 
 
Each patient underwent three 177Lu-PSMA therapies and three 68Ga-PSMA scans. 
The decision for 177Lu-PSMA radioligand therapy was made by the local interdisciplinary 
tumor board at each therapy center. The protocol followed for therapy has already been 
explained in detail by rhaber et all (Rahbar et al., 2017). The parameters used to assess the 
response to 177Lu-PSMA therapy for each therapy were pre and post therapy changes in 
levels of PSA (prostate specific antigen), serum and bone alkaline phosphate and Eastern 
Cooperative Oncology Group (ECOG) criterion. Data were collected for consecutive three 
177Lu-PSMA therapies. For calculation of overall survival, the time between the first PET/CT 
examination and the date of death was used. 
2.3.6 Statistical Analysis 
 
Receiver-operating-characteristics (ROC) analysis was performed using MedCalc software 
(version 12.3.0.0; MedCalc). ROC analysis was performed to estimate the optimal cutoff 
value of the correlating parameters for response assessment. For this purpose, the Youden 
index was used to maximize the sum of sensitivity and specificity (Youden, 1950). The area 
under the curve (AUC) was calculated for each parameter using the nonparametric method 
developed by Hanley and McNeil (Hanley and McNeil, 1982) representing the overall 
predictive or prognostic performance. For AUCs, exact binominal confidence intervals were 
calculated (95% confidence level), indicating the statistical significance of predictive 
capability if the critical value of 0.5 is not included.  
 
The relationship of the investigated parameters with overall survival, was analyzed 
using Kaplan–Meier plots. Kaplan–Meier analysis was performed using thresholds 
previously established by ROC analysis. Differences between Kaplan–Meier curves were 
evaluated using nonparametric log-rank tests, considering differences with a P value 
smaller than 0.05 to be significant. 
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3. Results 
The study showed some very good results. As in previous sections the results will 
also be divided into three parts. 
3.1 Role of textural heterogeneity parameters in diagnosis of          
pseudoprogression in high grade gliomas 
 
3.1.1 Patient characteristics 
 
The study population comprised 14 patients (Table 5) with histologically proven high-
grade glioma. A methylated MGMT promoter was found in 12 and a non-methylated MGMT 
promoter in 2 patients. All patients underwent radiotherapy before PET investigation, either 
concomitant with chemotherapy or separated. Nine patients included in the study 
underwent FET-PET investigation while during first-line treatment whereas five patients 
after relapse had occurred.  
 
3.1.2 Diagnosis of true tumor progression versus pseudoprogression 
 
Four of fourteen patients had confirmed PSP. Ten patients were regarded as having 
unequivocal progression (Table 6). All patients diagnosed with PSP had a methylated 
MGMT promoter whereas the MGMT promotor was methylated in 80% (8 of 10) in patients 
with true tumor progression. 
 
3.1.3 Identification of FET-PET-based subtypes 
 
As shown in Figure 5a, the consensus matrix displays a well-defined 3-block 
structure for k=3, corresponding to three distinct cluster groups. The cumulative distribution 
function (CDF) curve, which plots consensus distributions for each k, approaches at k=3 the 
ideal step function and its shape hardly changes as k is increased past 3 (Figure 5b). The 
difference between two CDF curves (at k and k+1) is summarized by measuring the area  
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1 1 m 29 AA yes 1 P: B,RT+TMZ no 7 Stable 27.2 >26.7 >27.2 
3 1 m 45 GBM* yes 2 P: B,TMZ; 1R: R,RT,PC yes 16 prog. 16.4 8.4 16.4 
4 1 f 40 AOA yes 4 P: pR; 1R: TMZ; 2R: 
TMZ; 3R: pR,RT, CCNU 
no 34 prog. 126.4 >26.1 >126.4 
10 1 m 43 GBM* no 1 P: pR,RT,PC no 37 prog. 24.1 8.0 24.1 
12 1 m 70 GBM yes 2 P: pR,RT+TMZ,TMZ;  
1R: R,TMZ 
no 139 prog. 45.1 4.1 45.1 
14 1 f 68 GBM yes 1 P: cR,RT+TMZ,TMZ yes 10 prog. 23.4 >22.1 >23.4 
5 2 f 49 GBM no 1 P: pR,RT+TMZ,TMZ no 52 prog. 34.1 4.6 34.1 
6 2 m 61 GBM yes 2 P: cR,RT+TMZ,TMZ;  
1R: R,RT,CCNU/TMZ 
no 25 prog. 23.5 >13.3 >23.5 
8 2 m 60 GBM yes 1 P: cR,RT+TMZ,TMZ no 33 prog. 11.3 2.2 11.3 
13 2 m 54 GBM yes 1 P: pR,RT+TMZ no 4 prog. 10.0 6.0 10.0 
2 3 m 59 GBM yes 1 P: R,RT+TMZ/CCNU, 
TMZ/CCNU 
no 95 stable 44.3 >21.7 >44.3 
7 3 f 47 AA yes 1 P: B,RT+TMZ,TMZ no 25 stable 27.5 16.7 27.5 
9 3 f 66 GBM yes 1 P: cR,RT+TMZ,TMZ no 48 prog. 21.7 5.1 21.7 
11 3 m 50 GBM yes 2 P: cR,RT+TMZ,TMZ; 
1R:R,RT+CCNU/TMZ, 
CCNU/TMZ 
no 41 stable 49.3 13.9 49.3 
 
Table 6: Patient Characteristics 
 
Abbreviations: AA, anaplastic astrocytoma; Clin., clinical follow-up.; cR, complete resection; Dx, 
diagnosis; Follow-up Time, time from diagnosis to last follow-up; GBM*, secondary glioblastoma; 
GBM, glioblastoma; CCNU, lomustine; MGMT, O-6-methylguanine-DNA methyltransferase; stable, 
no progression; nyr, not yet reached; PET, positron emission tomography; pR, partial resection; 
prog., progression; R, resection of unknown extent; RT, radiotherapy; RT+CCNU/TMZ, combined 
radiotherapy and chemotherapy with temozolomide and lomustine; RT+TMZ, combined 
radiotherapy and chemotherapy with temozolomide; TMZ, temozolomide; wk, weeks; y, years; B, 
biopsy; OS, overall survival; PC, procarbazine and lomustine; PFS, progression-free survival; m, 
months, # Line of therapy while under PET investigation; >, indicates censored values 
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under the CDF curves for k=2 through 7 and shown in Figure 5c. As k is increased, the area 
under the CDF curve stays approximately the same until k=3 and drops off significantly 
beyond that value. Any further increase in k does not come along with a corresponding 
marked increase in the CDF area, thus further supporting the choice of an optimal k=3. 
 
 
 
 
ill 5: Consensus matrix heat map 
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This result was confirmed by using the recently published PAC method, which was shown 
to be more accurate in determining the right number of k, where PAC was lowest at k=3, 
reflecting an optimal clustering with three groups. Of the 14 patients in our cluster cohort, 
six patients were assigned to cluster 1 (43%), and four patients (29%) each were assigned 
to cluster 2 and 3. 
 
3.1.4 Assigning FET-PET features to each cluster 
 
To identify FET-PET features associated with each cluster we used the nearest 
shrunken centroid method called predictive analysis of microarrays (PAM). Predictor 
discovery by PAM identified ten PET features out of 19 with at least one nonzero 
component. This implies that those selected features simultaneously distinguish all clusters 
from each other. Figure 6a shows a heatmap of all hierarchically clustered features 
corresponding to each cluster and Figure 6b shows the shrunken differences for the ten 
PET characteristics differentially regulated across the three clusters. Of those, 8 
characteristics are textural features (Contrast, Entropy, Correlation, Size Var, Coarseness, 
Volume, COV, and Complexity) and two are recognized as conventional (TLG, Max). 
Notably, the upper 7 (figure 6b) of those 10 features provide the most distinct separation 
among clusters: Contrast, Volume, Entropy, TLG, Correlation, Size Variation, and 
Coarseness. 
From the distribution of FET-PET features across clusters using PAM, it becomes evident 
that cluster 2 was particularly associated with high values of the textural characteristics 
Contrast and Entropy (Figure 6b). As increased values of both features have been tied to 
intratumoral tracer uptake heterogeneity, the cluster 2 phenotype was designated "high 
heterogeneity cluster". Except for the feature Coarseness, cluster 3 was largely associated 
with inverse loadings of FET-PET textural features as compared with cluster 2, most 
strikingly Entropy, Correlation and Size zone variability. With high intratumoral tracer uptake 
heterogeneity, Entropy and Correlation are known to be increased and Size-zone variability 
decreased. It was thus named "low heterogeneity cluster". Interestingly, TLG was also 
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comparably downregulated in this cluster. As opposed to cluster 2 and 3, cluster 1 had the 
least variability in features. Only the feature Correlation was considerably upregulated. As 
such, cluster 1 was defined as "intermediate cluster".  
 
3.1.5 Pseudoprogression and cluster assignment 
 
All of the patients assigned to cluster 2 (4 out of 4) and five out of six of cluster 1 
were diagnosed with progression, whereas three of four patients with pseudoprogression 
fell into cluster 3 (Figure 6a). 
 
 
 
ill 6: Cluster analysis 
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Usually, patients with suspected pseudoprogression and an increased TNRmax value 
(optimal cutoff of 2.1 in this study) were diagnosed with tumor progression. Figure 5c 
illustrates the explorative comparison of the diagnostic value in detecting true tumor 
progression of TNRmax with an assignment to cluster 3. Cluster 3 seems to be stronger 
associated with the detection of true progression (p=0.041) compared to increased 
TNRmax group (p=0.07). Cluster 3 provided a high sensitivity and specificity (90% and 
75%, respectively) for detecting true progression with a negative predictive value (NPV) of 
75%. TNRmax similarly provided high values for specificity and sensitivity (70% and 100%, 
resp ectively), yet, at the cost of a low NPV (57%). 
 
3.1.6 Putative prognostic value of clusters 
 
To investigate further each cluster phenotype, we calculated the progression-free 
survival (PFS) measured from the time of PET investigation to the date of following tumor 
progression based on RANO evaluation. As shown in Figure 7a, patients grouped to cluster 
2 seem to have a lower median PFS (5.3 months vs. 14.6 months in cluster 1 and 15.3 
months in cluster 3). When calculating median PFS using Kaplan-Meier method – 
accounting for censored values - cluster 2 remains the one with the lowest median PFS (4.6 
months vs. 8.4 months in cluster 1 and 13.9 months in cluster 3). Figure 7b illustrates that 
this effect might not be explained by differentially distributed prognostic factors among 
clusters, given a balanced distribution of prognostic factors. 
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ill 7: Progression free survival analysis 
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3.2 Role of textural heterogeneity parameters in patient selection for 177Lu-
PSMA therapy 
 
Seventy patients were evaluated in this study. Decrease in PSA level was observed 
in 42 patients (60%) and they were labeled as responders to therapy. Increase in PSA level 
was seen in 28 patients (40%) considered as non-responders (Figure 8(a)).  
 
 
ill 8(a): Percentage change in PSA 
 
41 patients (58%) showed response via decrease in serum alkaline phosphate level 
(Figure 8(b)) and 39 patients (55%) showed response by decrease in bone specific alkaline 
phosphate (Figure 8(c)). Among the responders 24 patients (34.2%) showed decrease in 
both PSA and alkaline phosphate levels at the same time while 22 patients (31.42%) 
showed decrease in PSA, alkaline phosphate and bone specific alkaline phosphate levels 
together. No change was observed in ECOG of any patient.  
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ill 8(b): Percentage change in Alkaline Phosphate 
 
ill 8(c): Percentage change in Alkaline Phosphate Bone 
Analysis of PET based heterogeneity parameters revealed that only two textural 
heterogeneity parameters entropy and homogeneity showed correlation with change in pre 
and post therapy PSA levels. PSA levels which showed correlation were derived from bone 
lesions. Lymph node and other lesions derived values did not show any correlation. Change 
in pre and post therapy values of serum alkaline phosphate, bone specific alkaline 
phosphate and individual patient ECOG status derived from all types of lesions remained 
uncorrelated. Similarly textural heterogeneity parameters other than entropy and 
homogeneity also remained uncorrelated. Actual values of correlating parameters as 
obtained through Spearman correlation are as under. 
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Entropy showed a negative correlation (rs = -0.327 and p = 0.006) and homogeneity 
showed a positive correlation (rs = 0.315 and p = 0.008) with change in pre and post 
therapy PSA levels (Figures 9 (a) and (b)).  
ill 9(a): Representation of negative 
correlation between absolute ∆PSA(ng/ml) 
and entropy of bone lesions (R2 = 0.283) 
ill 9(b): Representation of positive 
correlation between absolute ∆PSA 
(ng/ml) and homogeneity of bone lesions 
(R2 = 0.326) 
It is essential to be taken into account that change in PSA levels was obtained as 
post therapy levels minus the pre therapy level (post therapy PSA – pre therapy PSA). A 
negative value of this equation meant that post therapy PSA was less than that of pre 
therapy and the case was considered as of a responder. So the resultant value of a 
responder was negative and vice versa. Hence, a negative correlation of entropy with this 
change (also represented with a negative value) meant that entropy and change in PSA 
levels was directly proportional to each other. Or in other words the responders showed a 
higher entropy value. Similarly, homogeneity showed a positive correlation and hence a 
negative proportionality with the change in PSA levels signifying that the responders had a 
lower homogeneity.  
Below is a table (Table 7) summarizing the positive results i.e. obtained by 
correlating positive textural heterogeneity parameters obtained from bone lesions with 
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change in pre and post therapy PSA levels. Rest of the parameters are also given for 
comparison. It can be also seen that SUV values also did not positively correlate. 
PET Parameter 
(Bone Lesions) 
Correlating 
Clinical Parameter 
Spearman 
Coefficient 
p-value 
Entropy ∆PSA 0.327 0.006 
Homogeneity ∆PSA -0.315 0.008 
COV ∆PSA 0.113 0.516 
Contrast ∆PSA 0.257 0.136 
Size Variation ∆PSA -0.309 0.071 
SUV( mean) ∆PSA 0.168 0.333 
 
Table 7: Correlation of bone lesion derived PET parameters with change in PSA level 
The ROC analysis also showed that entropy and homogeneity are statistically 
significant (p < 0.05) for predictive ability.  Further results of ROC analysis are summarized 
in the table below (Table 8).  
Parameter AUC 
(Area under 
curve) 
95% Confidence 
Interval 
Cut-off Value 
(based on Youden 
Index) 
Entropy 0.695 0.573 to 0.799 >5.15 
Homogeneity 0.683 0.561 to 0.789 ≤0.43 
Table 8: Results of ROC Analysis for Predictive Value of Pre therapeutic PET- CT 
Sensitivity and specificity was also assessed for both parameters through ROC 
(Figure 10(a)and (b)) and these values were used to find out positive and negative 
predictive values (Table 9).  
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Ill 10 (a) and (b): Showing results of ROC analysis 
 
Parameter Sensitivity Specificity Positive Predictive 
Value 
Negative Predictive 
Value 
Entropy 71.4 % 71.4 % 62.50 % 78.95 % 
Homogeneity 81 % 57.1 % 66.67 % 73.91 % 
 
Table 9: Outcomes of positive parameters 
 
For the above mentioned parameters, the combined sensitivity of entropy and homogeneity 
for predicting outcome was 57.83% and the combined specificity was 87.74%. 
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3.3 Role of Tumor Textural Heterogeneity in 68Ga-PSMA PET-CT for Therapy           
Response Assessment and Prognosis in Prostate Cancer Patients 
 
Fifty patients were evaluated in this study. Decrease in PSA level was observed in 
31 patients (62%) and they were labeled as responders to therapy. Increase in PSA level 
was seen in 19 patients (38%) considered as non-responders.  
 
29 patients (58%) showed response via decrease in serum alkaline phosphate level 
and 27 patients (54%) showed response by decrease in bone specific alkaline phosphate. 
No change was observed in ECOG of any patient till the completion of third therapy. 
 
Analysis of heterogeneity parameters in the bone lesions showed that three 
parameters had statistically significant predictive capability. These three parameters were 
entropy, homogeneity and intensity variation. The significance of parameters was 
ascertained through independent T-test and ROC analysis. Conventional parameters SUV 
mean and max did not show any statistical significance. Similarly, lesions in lymph nodes 
and other organs (liver, prostate) did not show any statistical significance. 
 
The ROC analysis was performed for changes in measured for pretherapeutic PET-
CT, mid-therapy PET-CT and post-therapy PET-CT examinations. The results of these 
measurements are presented in Table 10. 
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Parameter AUC 95% Confidence Interval p-value (0.05) 
Pre-Therapy  
Entropy 0.725 0.546-0.864 0.018 
Homogeneity 0.603 0.421-0.766 0.030 
Intensity Variation 0.659 0.477-0.812 0.05 
Mid-Therapy  
Entropy 0.687 0.505-0.834 0.042 
Homogeneity 0.679 0.498-0.828 0.057 
Intensity Variation 0.681 0.500-0.830 0.06 
Post-Therapy  
Entropy 0.712 0.532-0.854 0.001 
Homogeneity 0.755 0.577-0.885 0.002 
Intensity Variation 0.716 0.536-0.857 0.038 
 
Table 10: Results of ROC analysis 
In the pretherapeutic scans entropy had the highest AUC and the lesions with higher 
entropy and intensity variation and low homogeneity showed better response to the first 
therapy. While in the post-therapy scans homogeneity showed the highest AUC and the 
lesions with higher homogeneity and lower entropy showed better response to therapy. 
This is in contrast with the pretherapeutic scan results. The lesions having persistently 
higher entropy and size variation or lower homogeneity showed poor prognosis after three 
therapies. We found that in pre-therapy scans a higher entropy and size variation and 
lesser homogeneity was good selection criterion for patients but after subsequent therapies 
(three in our study) lower entropy and size variation and higher homogeneity were 
indicators of good outcome. 
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      ill 11: ROC analysis 
No statistically significant correlation was found between the textural parameters and 
lesion volume. In addition, the positive outcomes were obtained only for bone lesions and 
only those in comparison to change in serum PSA levels. The lymph node lesions showed 
no statistical significance and similarly, correlation with alkaline phosphate, bone alkaline 
phosphate and ECOG criterion was also not statistically significant. 
The sensitivity and specificity of the parameters was also calculated for predicting 
outcome with change in PSA as standard. The results are showed in following table.  
Parameter Sensitivity Specificity 
Pre-Therapy 
Entropy 79.2 % 46.1 % 
Homogeneity 69.4 % 57.1 % 
Intensity Variation 42.8 % 84.6 % 
Mid-Therapy 
Entropy 57.1 % 84.6 % 
Homogeneity 61.9 % 84.6 % 
Intensity Variation 57.1 % 76.9 % 
Post-Therapy 
Entropy 85.7 % 61.5 % 
Homogeneity 42.8 % 100 % 
Intensity Variation 80.9 % 69.2 % 
 
Table 11: Sensitivity and specificity of parameters 
During a mean follow-up of 900 days, progressive disease was found in 19 patients. 
Increased PSA levels were detected in all patients with progression. Fifteen patients of the 
study group died within the follow up time, on average 510 days after the first PET-CT 
examination (range, 187 - 776 days).  
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ill 12 : Kaplan-Meier analysis 
Kaplan–Meier analysis showed all three parameters to have a statistically significant 
prognostic capability for overall survival analysis. The corresponding Kaplan–Meier plots 
are shown in figure 3.  
p-values indicating a prognostic capability are shown in the graphs. It can be seen 
that entropy shows the most statistically significant capability to predict overall survival from 
pre, mid and post therapy scans. However, homogeneity and intensity variation were able 
to predict survival only from the data acquired via post-therapy scans. We also calculated 
combined sensitivity and specificity for all three predictors from the values obtained by post 
therapy scan. 
Combined sensitivity of entropy and intensity variation for predicting outcome was 
69.3 and the combined specificity was 88.1 
Combined sensitivity of entropy and homogeneity for predicting outcome was 91.9 
and the combined specificity was 61.5 
The median overall survival for entropy which proved to be the best indicator in 
analysis is shown in the table below. 
Time Point Parameter Mean Overall 
Survival  
Pre-therapy  Entropy ≥ 5.06 722 days 
Entropy < 5.06 376 days 
Mid-therapy Entropy ≥ 5.87 701 days 
Entropy < 5.87 436 days 
Post-therapy  Entropy ≤ 5.38 624 days 
 Entropy > 5.38 254 days 
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 To investigate whether the tumor heterogeneity or the change in heterogeneity 
during therapy depended on the lesion size or the change in lesion size, we performed a 
Pearson correlation analysis of positive parameters for heterogeneity with the lesion 
volume. No correlation was found between lesion volume and textural heterogeneity 
parameters in all parts of the study. 
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4. Discussion 
 
In this study, we analyzed the capability of textural markers to assess heterogeneity 
in PET to predict therapy response and outcome in patients. Assessment of tumor  
heterogeneity is becoming an effective tool for analysis of tumor and therapy behaviors. 
Most important is this analysis can be performed on in depth image analysis and is much 
easier and efficient than the invasive methods. Instead of being only a qualitative analysis, 
analysis of textural heterogeneity helps in extracting quantitative information from the 
images as well (Aerts et al., 2014). Textural analysis is the measure of spatial variation at 
different levels of a tumor like imaging, gross morphology, cellular and genetic level. It is 
known that multiple subclonal populations coexist within tumors, reflecting extensive 
intratumoral somatic evolution (Yachida et al., 2010; Gerlinger et al., 2012). This 
heterogeneity is a clear barrier to the goal of personalized therapy based on molecular 
biopsy-based assays, as the identified mutations and gene-expression does not always 
represent the entire population of tumor cells (Gerlinger and Swanton, 2010; Kern, 
2012).  
 
Genetic variations in tumors can be related to a mutator phenotype that generates 
new clones, some of which expand into large populations (Nowell, 1976). However, 
although identification of genotypes is of substantial interest, it is insufficient for complete 
characterization of tumor dynamics because evolution is governed by the interactions of 
environmental selection forces with the phenotypic, not genotypic, properties of populations 
as shown, for example, by evolutionary convergence to identical phenotypes among cave 
fish even when they are from different species (Greaves and Maley, 2012; Vincent and 
Brown, 2005; Gatenby and Gilles, 2008). This connection between tissue selection forces 
and cellular properties has the potential to provide a strong bridge between medical 
imaging and the cellular and molecular properties of cancers (Gatenby et al., 2013). Thus it 
can be said that continued tumor variation/evolution can be attributed to tumoral 
heterogeneity at genetic level. Evolution within tumors is governed by Darwinian dynamics, 
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with identifiable environmental selection forces that interact with phenotypic (not genotypic) 
properties of tumor cells in a predictable and reproducible manner; clinical imaging is 
uniquely suited to measure temporal and spatial heterogeneity within tumors that is both a 
cause and a consequence of this evolution (Gatenby et al., 2013). Analysis of this spatial 
variation by computer generated algorithms working on superimposition of multiple 
sequined images can lead to individual specific evaluation of intratumoral variation and can 
thus form a basic factor for personalized therapy.  
 
PET being a multimodal modality for imaging, giving both the anatomical and 
physiological information is gaining momentum for analysis of tumor textural heterogeneity. 
When considering the PET component, it refers to radiotracer uptake spatial distribution, 
which may reflect, depending on the radiotracer used, the combination of underlying 
biological processes such as metabolism, hypoxia, cellular proliferation, vascularization and 
necrosis (Willaime et al., 2013; Weber et al., 2000). Regarding the low-dose CT component 
of PET-CT, usually without contrast enhancement, heterogeneity refers to the variability in 
tissue density, which may result from spatially varying vascularization, necrosis or 
cellularity, as well as the proportions of fat, air and water (Aerts, 2014). With other 
modalities such as contrast-enhanced CT, as well as in MRI using various sequences (for 
example, T1, T2, FLAIR, DCE-MRI), heterogeneity can also include the spatial variability of 
vessel density, perfusion, proton density and physiological tissue characteristics (Win et al., 
2013; Asselin et al., 2012; Yoon et al., 2016).  
 
In the recent years a lot of effort has been put into textural heterogeneity parameters 
as analyzed by PET-CT to assess tumor behavior and its responsiveness to therapy. One 
of the biggest reasons for this paradigm shift towards textural heterogeneity was that the 
conventional PET parameters which are usually considered as outcome predictors in 
clinical as well as research studies failed to provide sufficient information regarding various 
properties of tumor (O’Sullivan et al., 2003).  These conventional parameters include 
maximum or mean standardized uptake value (SUVmax and SUVmean) or the metabolically 
active tumor volume (MATV). Some of these properties, such as shape and uptake 
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heterogeneity, may reflect different tumor profiles associated with their aggressiveness, 
metastatic potential, or degree of response to a specific treatment, and consequently 
prognosis (Basu et al., 2011; Visvikis et al., 2012). However, quantification of these 
properties could provide information with higher clinical value than the usual metrics in 
selection of patients or identifying poor responders to treatment. 
 
The use of textural analysis in the evaluation of PET images was first shown by El 
Naqa and colleagues in a seminal study in 9 patients with head and neck cancer and 14 
patients with cervix cancer (El Naqa et al., 2009). Study comprised of investigating 
intensity-volume histogram metrics and shape and texture features extracted from PET 
images to predict patient's response to treatment. The preliminary results suggested that 
the proposed approaches could potentially provide better tools and discriminant power for 
utilizing functional imaging in clinical prognosis. Only two other studies investigating textural 
analysis in PET were published in the two following years. The first demonstrated the 
impact of parameters used in PET iterative image reconstruction algorithms on textural 
analysis metrics, of which many were shown to be sensitive to the resulting varying 
characteristics of the reconstructed images (Galavis et al., 2010). The second study 
investigated the predictive value of FDG uptake heterogeneity quantified using textural 
analysis, in 41 patients with locally advanced oesophageal cancer receiving concomitant 
chemoradiotherapy, and showed that textural analysis metrics have higher predictive value 
than SUV (Tixier et al., 2011).  
 
In CT and MRI images several studies have shown that the textural analysis can be 
linked at the level of genomics through some pathophysiological processes constantly 
altering the innate tumor behavior. These studies (Segal et al., 2007; Gevaert et al., 2014; 
Wan et al., 2016) are very relevant for assessment of clinical data. A study established a 
correlation between perfusion CT-derived parameters (e.g. blood flow) and texture analysis 
metrics from FDG PET in stage HI/TV colorectal tumor’s (Tixier et al., 2014). Regarding the 
relationship between PET textural analysis features and data from underlying scales, 
preliminary results from a prospective study in 54 patients with head and neck cancer have 
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recently been presented, and demonstrate that some PET textural analysis metrics could 
be linked to altered signaling pathways related, for example, to cell proliferation and 
apoptosis (Tixier et al., 2015). 
 
 Studies like these can help us understand the added advantage of tumor textural 
analysis over the conventional PET parameters, which enhances the clinical value of the 
studies. However, major number of studies available are performed with FDG-PET. In our 
analysis to see the sensitivity and specificity of textural analysis in other radiotracers we 
used 18F-FET PET and 68Ga-PSMA PET. This was done in order see the predictive ability 
of this analysis with a varied number of radiotracers and also to study the tumoral variation 
and treatment response in different tumors. Depending on radiotracer and patient 
population our study was divided in three parts. We will individually discuss each of those.  
 
Objective of the first part of study was to distinguish between true tumor progression 
and pseudoprogression in the patients of high grade glioma in FET-PET using textural 
heterogeneity parameters as compared to the conventional PET parameters. As described 
earlier the accurate and timely distinction between actual tumor progression and 
pseudoprogression (which is a sequel of chemoradiation) is very important, as it can effect 
significantly on further therapy planning and patient outcome. 
 
The results of this study suggested that high grade glioma patients with suspected 
pseudoprogression could be classified into 3 distinct clusters, solely based on a set of 
textural FET-PET features. Most of the patients assigned to cluster 3 had 
pseudoprogression while all patients assigned to cluster 2 had true tumor progression. 
Thus, textural FET-PET feature analysis lent itself as a novel useful non-invasive tool, 
besides the frequently used TNRmax to distinguish pseudoprogression from true tumor 
progression in patients with high grade glioma. 
 
When we compared the value of pseudoprogression prediction using a cluster-based 
classifier (cluster 3), that was based on textural PET features, against the most widely used 
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PET marker TNRmax (Galldiks et al., 2015; Kebir et al., 2016) only the cluster-based 
classifier was significantly associated with pseudoprogression detection. In the study 
(Galldiks et al., 2015) the objective was to assess the clinical value of O-(2-(18)F-
fluoroethyl)-L-tyrosine18F-FET PET in the differentiation of pseudoprogression and early 
tumour progression  after radiochemotherapy of glioblastoma. A group of 22 glioblastoma 
patients with new contrast-enhancing lesions or lesions showing increased enhancement 
(>25 %) on standard MRI within the first 12 weeks after completion of radiochemotherapy 
with concomitant temozolomide (median 7 weeks) were additionally examined using amino 
acid PET with 18F-FET. Maximum and mean tumour-to-brain ratios (TBRmax, TBRmean) 
were determined. Classification as pseudoprogression or actual tumor progression was 
based on the clinical course (no treatment change at least for 6 months), follow-up MR 
imaging and/or histopathological findings. Pseudoprogression was confirmed in 11 of the 
22 patients. In patients with pseudoprogression, 18F-FET uptake was significantly lower 
than in patients with actual progression (TBRmax 1.9 ± 0.4 vs. 2.8 ± 0.5, TBRmean 1.8 ± 0.2 
vs. 2.3 ± 0.3; both P < 0.001) and presence of MGMT promoter methylation was significantly 
more frequent (P = 0.05). Receiver operating characteristic analysis showed that the 
optimal (18)F-FET TBRmax cut-off value for identifying pseudoprogression was 2.3 
(sensitivity 100 %, specificity 91 %, accuracy 96 %, AUC 0.94 ± 0.06; P < 0.001). In 
comparison to that in our study the negative predictive value was higher with the cluster-
based classifier, cluster 3. 
 
Out of a set of 19 FET-PET features encompassing conventional (among others 
TLU, TNRmax, and TNRmean) as well as textural features, only 10 features separated all 3 
clusters from one another. Of those 10, 7 features, namely Contrast, Volume, Entropy, 
TLU, Correlation, Size-zone var., and Coarseness were most differentially regulated among 
clusters and all of the latter 7 – except for TLU and Volume - are considered textural PET 
markers (30). These textural features reflect intratumoral uptake heterogeneity and may be 
used to quantify tumor heterogeneity (Tixier et al., 2011). The degree of intratumoral 
heterogeneity is suspected to be a prognostic factor (Almendro et al., 2013). Some textural 
markers such as Entropy and COV have been shown to be prognostically relevant in 
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systemic tumors (Almendro et al., 2013). Intriguingly, cluster 2, which included only patients 
with true progression, exhibited high values of heterogeneity markers (particularly Contrast 
and Entropy). By contrast, cluster 3, which included largely patients with confirmed 
pseudoprogression, was associated with low values of heterogeneity markers. On the other 
hand, TLU, the only non-textural marker of the 7 highly differentially regulated FET-PET-
features, has been shown to be negatively correlated with prognosis and - compared to 
other conventional PET features - a stronger predictor of outcome in systemic tumors 
(Hyun et al, 2016; Choi et al., 2013). Interestingly, TLU was inversely associated with 
cluster 3, supporting that the cluster assignment based on our set of PET features might 
carry prognostic implications. 
 
Similarly, in a recently published retrospective study (Pyka et al., 2016) of patients 
with high grade glioma, who received FET-PET prior to first-line treatment, 3 of the textural 
markers assessed here, namely complexity, contrast and coarseness, were shown to be 
possibly correlated with survival. All patients received static FET-PET scans prior to first-
line therapy. TBR (max and mean), volumetric parameters and textural parameters based 
on gray-level neighborhood difference matrices were derived from static FET-PET images. 
All FET-PET textural parameters showed the ability to differentiate between World Health 
Organization (WHO) grade III and IV tumors (p < 0.001; AUC 0.775). Further improvement 
in discriminatory power was possible through a combination of texture and metabolic tumor 
volume, classifying 85 % of tumors correctly (AUC 0.830). Determination of uptake 
heterogeneity in pre-therapeutic FET-PET using textural features proved valuable for the 
(sub-)grading of high-grade glioma as well as prediction of tumor progression and patient 
survival, and showed improved performance compared to standard parameters such as 
TBR and tumor volume. In our very patient cohort, cluster 2 patients showed the lowest 
median PFS and OS compared to patients from the other clusters. Notably, canonical 
prognostic markers were similarly distributed among clusters and are not suited to explain 
this observation. However, survival times varied considerably among patients sharing the 
same cluster and the sample size was too small to draw strong conclusions from this pilot 
data. In addition, it should be mentioned that our cohort consisted of five patients who 
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underwent PET after relapse had occurred. With the other patients included in the first-line 
therapy, our cohort was heterogenous to some degree although those patients included 
after relapse were treated with again with alkylating (radio)chemotherapy. This cohort 
heterogeneity and the issue that treatment at recurrence might further account for varying 
PET data makes interpretation difficult. Nevertheless, because our findings might indicate a 
putatively prognostic value of clusters defined by textural FET-PET markers reflecting 
intratumoral uptake heterogeneity, a prospective study with a larger patient cohort 
validating our results is warranted.  
 
In summary, this work provided a novel and interesting approach to FET-PET based 
identification of pseudoprogression from actual tumor progression. The textural 
heterogeneity can be easily incorporated into routine PET investigations. The ability of the 
study to provide us with this important discrimination can give a lot of clinical benefit. 
Patients with diagnosis of actual tumoral progression can undergo further therapy resulting 
in decreased morbidity and mortality, while patients with a true diagnosis of 
pseudoprogression can then avoid undergoing any unnecessary treatment. However, as 
mentioned above, by virtue of the small sample size interpretation of our results is limited 
and calls for validation in larger and systemic analyses. Nevertheless, this approach is 
novel, the results are promising, and encourage analyzing the diagnostic value of textural 
markers in a larger cohort of patients. 
 
 In the second and third parts of our study, we analyzed the predictive capability of 
textural heterogeneity parameters in patients undergoing 177Lu-PSMA therapy for 
determination of patient selection criteria, treatment outcome and survival analysis.  
PSMA bound ligands have started gaining acceptance for diagnosis and treatment of 
prostate cancer (Rahbar et al., 2017; Kulkarni et al., 2016; Baum et al., 2016). The 
retrospective German multicenter analysis (Rahbar et al., 2017) showed that 177Lu-PSMA-
617 radioligand therapy demonstrated favorable safety and high efficacy exceeding those 
of other third-line systemic therapies in metastatic castration resistant prostate cancer 
patients. PSA decline occurred in 65% of patients after 1 cycle of radioligand therapy with 
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177Lu-PSMA-617 and in 72% after the second cycle. There are still almost 30% of the 
patients who did not show or showed less than 50% decline in serum PSA level. It is very 
important to identify those patients and so that therapy modifications might be performed 
which can then help in increasing the efficacy of treatment. Our study aimed at utilization of 
heterogeneity parameters in an effort to improve the selection criterion of patients and 
acted as a means to predict improved outcome. To achieve this effect at the earliest 
possible time, prior to therapy planning analysis was performed on the data collected from 
baseline scan. Our study showed a potential for response prediction through baseline 
PSMA-PET-CT scan using textural features. It also suggested that more heterogeneous the 
tumor was in PSMA expression more responsive it was to PSMA therapy, thus contributing 
efficiently towards patient selection, treatment planning and improvement in overall 
diagnostic accuracy. The ROC analysis showed that two textural heterogeneity parameters 
entropy and homogeneity were statistically significant (p < 0.05) for predictive ability as 
obtained from the baseline 68Ga-PSMA scan prior to 177Lu-PSMA therapy. Spearman 
correlation showed that entropy showed a negative correlation (rs = -0.327 and p = 0.006) 
and homogeneity showed a positive correlation (rs = 0.315 and p = 0.008) with change in 
pre and post therapy PSA levels.   
 
Predictive ability of various parameters from the baseline scan has also been 
investigated. In a study (Ferdinandus et al., 2017) the effect of different pretherapeutic 
parameters on the therapeutic response measured by prostate-specific antigen (PSA) 2 
months after radioligandtherapy. In the univariate analysis, younger age, higher levels of γ-
glutamyl transferase, lower pretherapeutic hemoglobin, a higher Gleason score, a higher 
number of platelets, higher C-reactive protein, regular need for pain medication, and higher 
lactate dehydrogenase had a negative impact on the therapeutic response; however, the 
multivariate analysis revealed that the most significant independent factors were the 
number of platelets and regular need for pain medication. The response was independent 
of the amount of PSMA uptake as well as previous therapies and other measured factors. A 
PSA decline of more than 50% was observed significantly more in patients without a 
regular need for analgesics. Numerous studies have also reported the use of textural 
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heterogeneity parameters for the assessment of patient outcome. PET due to its ability for 
physiological imaging and hence having the ability to predict changes at molecular level 
and also having the added advantage of whole body imaging is an ideal choice for 
analyzing textural heterogeneity parameters.  
 
A study (Eary et al., 2008) proposed that heterogeneity in 18F-FDG spatial 
distribution can be used to predict tumor biologic aggressiveness. This study presented 
data to support the hypothesis that a new heterogeneity-analysis algorithm applied to 18F-
FDG PET images of tumors in patients was predictive of patient outcome. 18F-FDG PET 
images from 238 patients with sarcoma were analyzed using a new algorithm for 
heterogeneity analysis in tumor 18F-FDG spatial distribution. Statistical analyses show that 
heterogeneity analysis is a strong independent predictor of patient outcome. The new 18F-
FDG PET tumor image heterogeneity analysis method was validated for the ability to 
predict patient outcome in a clinical population of patients with sarcoma. It was proposed 
that this method could be extended to other PET image datasets in which heterogeneity in 
tissue uptake of a radiotracer may predict patient outcome.  
 
In another study (Cheng et al., 2013) the researchers investigated whether the 
textural features of pretreatment 18F-FDG PET-CT images could provide any additional 
prognostic information and clinical staging in patients with advanced T-stage oropharyngeal 
squamous cell carcinoma. Retrospective analysis of the pretreatment 18F-FDG PET-CT 
images of 70 patients was performed. The textural features of pretreatment 18F-FDG PET-
CT images were extracted from histogram analysis (SUV variance and SUV entropy), 
normalized gray-level cooccurrence matrix (uniformity, entropy, dissimilarity, contrast, 
homogeneity, inverse different moment, and correlation), and neighborhood gray-tone 
difference matrix (coarseness, contrast, busyness, complexity, and strength). Receiver-
operating-characteristic curves were used to identify the optimal cutoff values for the 
textural features. Multivariate Cox regression analysis showed that age, tumor TLG, and 
uniformity were independently associated with progression-free survival (PFS) and disease-
specific survival (DSS). TLG, uniformity, and HPV positivity were significantly associated 
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with overall survival (OS). A prognostic scoring system based on TLG and uniformity was 
derived. Uniformity extracted from the normalized gray-level co-occurrence matrix 
represented an independent prognostic predictor in patients with advanced T-stage 
oropharyngeal squamous cell carcinoma. A scoring system was developed and that might 
serve as a risk-stratification strategy for guiding therapy. In our study we also analyzed 
pretreatment 68Ga-PSMA scans of 70 patients. Two textural heterogeneity parameters 
entropy and homogeneity showed ability to predict outcome. However, the conventional 
PET parameters SUV mean and max did not show such ability. Tumor volume also had no 
effect on textural heterogeneity.  
 
Similarly in another study (Tixier et al., 2011) the aim was to propose and evaluate 
new parameters obtained by textural analysis of baseline PET scans for the prediction of 
therapy response in esophageal cancer. Forty-one patients with newly diagnosed 
esophageal cancer treated with combined radiochemotherapy were included in this study. 
All patients underwent pretreatment whole-body 18F-FDG PET. Different image-derived 
indices obtained from the pretreatment PET tumor images were considered. These 
included usual indices such as maximum SUV, peak SUV, and mean SUV and a total of 38 
features (such as entropy, size, and magnitude of local and global heterogeneous and 
homogeneous tumor regions) extracted from the 5 different textures considered. The 
capacity of each parameter to classify patients with respect to response to therapy was 
assessed using the Kruskal-Wallis test (P < 0.05). Specificity and sensitivity (including 95% 
confidence intervals) for each of the studied parameters were derived using receiver-
operating-characteristic curves. Relationships between pairs of voxels, characterizing local 
tumor metabolic non uniformities, were able to significantly differentiate all 3 patient groups 
(P < 0.0006). Regional measures of tumor characteristics, such as size of non-uniform 
metabolic regions and corresponding intensity non-uniformities within these regions, were 
also significant factors for prediction of response to therapy (P = 0.0002). Receiver-
operating-characteristic curve analysis showed that tumor textural analysis can provide 
non-responder, partial-responder, and complete-responder patient identification with higher 
sensitivity (76%-92%) than any SUV measurement. Textural features of tumor metabolic 
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distribution extracted from baseline 18F-FDG PET images allow for the best stratification of 
esophageal carcinoma patients in the context of therapy-response prediction. In our study 
the combined sensitivity of entropy and homogeneity for predicting outcome was 57.8% 
and the combined specificity was 87.7%. 
  
  It is interesting to note that in our results entropy showed a directly proportional 
correlation with change in pre and post therapy PSA levels while homogeneity showed an 
inverse relationship. In other words it can be inferred that more heterogeneous the tumor 
was, the better it responded to the PSMA therapy. As higher entropy is a measure of 
greater heterogeneity of the tumor. The patients which were labeled as responders owing 
to decrease in post PSMA therapy PSA levels showed a higher entropy in baseline scan. 
Similarly, the responders showed lower homogeneity in the baseline scan. Although we did 
define the response to therapy by PSA levels and did not correlate the textural features with 
patient outcomes, we have shown in previous studies, that a reduction of PSA after therapy 
with Lu-177 PSMA is a prognostic factor for overall survival (Ahmadzadehfar et al., 2016; 
Ahmadzadehfar et al., 2017). 
 
 In the study by Pyka T et.al. (Pyka et al., 2015), they evaluated the predictive value 
of textural heterogeneity parameters in FET-PET for recurrence and prognosis in non-small 
cell lung carcinoma (NSCLC) patients receiving primary stereotactic radiation therapy 
(SBRT). 45 patients with early stage NSCLC (T1 or T2 tumor, no lymph node or distant 
metastases) were included in this retrospective study and followed over a median of 
21.4 months (range 3.1–71.1). Pre-treatment FDG-PET/CT scans were obtained from all 
patients. SUV and volume-based analysis as well as extraction of textural features based 
on neighborhood gray-tone difference matrices (NGTDM) and gray-level co-occurence 
matrices (GLCM) were performed using InterView Fusion™ (Mediso Inc., Budapest, 
Hungary). ROC revealed a significant correlation of several textural parameters with local 
recurrence with an AUC value for entropy of 0.872. While there was also a significant 
correlation of local recurrence with tumor size in the overall cohort, only texture was 
predictive when examining T1 (tumor diameter < = 3 cm) and T2 (>3 cm) subgroups. In 
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univariate survival analysis, both heterogeneity and tumor size were predictive for disease-
specific survival, but only texture determined by entropy was determined as an 
independent factor in multivariate analysis (hazard ratio 7.48, p = .016). Overall survival 
was not significantly correlated to any examined parameter, most likely due to the high 
comorbidity in our cohort. This study showed that entropy has predictive potential for local 
recurrence with an AUC of 0.872. The study also showed that higher value of entropy was 
linked to poor outcome. In our study entropy was also a predictor for outcome with an AUC 
of 0.695 however, higher entropy showed better outcome for PSMA therapy. Similarly, 
another study (Soussan et al., 2014) discussed whether tumor heterogeneity measured 
using texture analysis in FDG-PET images is correlated with pathological prognostic 
factors in invasive breast cancer. Fifty-four patients with locally advanced breast cancer 
who had an initial FDG-PET were retrospectively included. In addition to SUVmax, three 
robust textural indices extracted from 3D matrices: High-Gray-level Run Emphasis 
(HGRE), Entropy and Homogeneity were studied. Univariate and multivariate logistic 
regression was used to identify PET parameters associated with poor prognosis 
pathological factors: hormone receptor negativity, presence of HER-2 and triple negative 
phenotype. Receiver operating characteristic (ROC) curves and the (AUC) analysis, and 
reclassification measures, were performed in order to evaluate the performance of 
combining texture analysis and SUVmax for characterizing breast tumors. Results showed 
that triple negative breast cancer (TNBC) exhibited higher SUVmax, lower Homogeneity 
non-TNBC. Tumor heterogeneity measured on FDG-PET was higher in invasive breast 
cancer with poor prognosis pathological factors. Texture analysis might be used, in 
addition to SUVmax, as a new tool to assess invasive breast cancer aggressiveness. In 
this study lower homogeneity was associated with poor outcome of breast cancer patients. 
However in our study lower homogeneity (AUC 0.683) was associated with better outcome.  
 
 An interesting question which arises here is whether a more heterogeneous tumor 
can respond better to the treatment? In many previous studies involving textural 
heterogeneity it was proven otherwise. Increased textural heterogeneity has already been 
linked with poor outcome. On the contrary, our study points in the opposite direction. One of 
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the reasons for this behavior could be that this phenomenon can possibly be highly tumor 
and therapy specific. PSMA shows significant over expression in metastatic, poorly 
differentiated and therapy refractory carcinomas. Treatment refractory tumors can have the 
presence of multiple clones resulting in formation of complex systems and contributing 
towards tumor heterogeneity (Ahmadzadehfar et al., 2016). Patients included in our study 
group had already metastatic disease which was treatment refractory. Therefore, we can 
assume that there was a significant PSMA overexpression in tumors of patients included in 
our study. More heterogeneous a tumor is, more PSMA expression it shows thereby 
increasing the uptake of PSMA bound ligands and thus responding better to therapy. In a 
very interesting study by Jeffrey West and Paul Newton (West and Newton, 2017) about 
Optimizing chemo-scheduling based on tumor growth rates discussed ways to optimize 
chemotherapeutic scheduling using a Moran process evolutionary game-theory model of 
tumor growth that incorporates more general dynamical and evolutionary features of tumor 
cell kinetics.  
 
 
ill. 13: The relationship between tumor cell reduction (TCR) and entropy (H) is shown for a 
single cycle of chemotherapy (a), 8 cycles (b), and 16 cycles (c). The low slope value in (a) 
indicates negligible advantage of high entropy strategies after only a single cycle. After 
many cycles, the advantage of high entropy strategies is apparent (b,c). 
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Using this model, and employing the quantitative notion of Shannon entropy they found out 
that which assigns high values to low-dose metronomic (LDM) therapies, and low values to 
maximum tolerated dose (MTD) therapies, we show that low-dose metronomic strategies 
can outperform maximum tolerated dose strategies, particularly for faster growing tumors. It 
proves the fact that over multiple cycles, higher entropy strategies have a bigger impact on 
faster growing tumors than on slower growing tumors. 
 
Our study showed as well that more heterogeneous a tumor is in PSMA expression 
better it responses to PSMA therapy. Higher entropy and lower homogeneity proved to be 
good predictors for favorable outcome. This could be especially important for patients with 
hormone treatment refractory prostate cancers which have already undergone multiple 
therapies prior to PSMA therapy and the resulting poor differentiation results in increased 
heterogeneity in cancer cells. PSMA with its specific property of over expression in 
hormone refractory, poorly differentiated and metastatic cancers can hence show better 
therapy response in such cases. All the patients in our study which were candidates for 
PSMA therapy were labeled as refractory to hormone treatment and several had undergone 
some other treatment options before as well. As, PSMA serves as a target of targeted 
therapy with 177Lu-PSMA, its over expression might result in better uptake of 
radiopharmaceutical. So, in pre-therapy analysis the patients with lesions having higher 
entropy and intensity variation and less homogeneity proved to be better targets for therapy 
and responded more to treatment.   
 
 Hence, firstly this study showed the possibility of extracting vital data via the 
analysis of baseline scan only which can directly predict the outcome of patient. This finding 
can be of excessive importance in selecting the patients which can possibly respond better 
by altering the treatment regimen. Secondly, this study differentiates the textural 
parameters which can be used for gaining outcome data and also points out their 
correlation with the outcome. 
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In the third part of our research, we analyzed the capability of textural inhomogeneity 
markers on PET to predict therapy response and outcome in patients with hormone 
refractory prostate carcinoma. The markers analyzed were determined before, during, and 
after completion of three 177Lu-PSMA therapies. Regarding the predictive capability, three 
parameters entropy, homogeneity and intensity variation showed statistical significance in 
all stages of study. For personalized therapy it is very important if outcome can be 
predicted in the start of therapy. The earlier the outcome is predicted the more beneficial it 
is for the patient. In the pre-therapy analysis entropy had the highest AUC (0.72) and a 
sensitivity of 95%. In the mid-therapy analysis again entropy showed the highest AUC 
(0.67). However, it was less than that of pre-therapy analysis. The highest specificity was 
showed by homogeneity in both pre and mid-therapy analyses. In the post-therapy analysis 
homogeneity showed the highest AUC (0.755). The highest specificity was again showed 
by homogeneity while entropy showed maximum sensitivity.  We also showed that there 
was no correlation between lesion volume and any of the positive parameters throughout 
the course of study. Numerous studies have investigated the predictive value of textural 
heterogeneity parameters for assessment of therapy response.  
 
In a study Lapa C. et. Al.,(Lapa et al., 2015) investigated the potential of 
somatostatin receptor subtype II (SSTR)-PET to assess intraindividual tumor heterogeneity 
and thereby treatment response prior to peptide receptor radionuclide therapy (PRRT).12 
patients with progressive radioiodine-refractory differentiated or medullary thyroid cancer 
were enrolled. SSTR-PET was performed at baseline. Conventional PET parameters and 
heterogeneity parameters were analyzed regarding their potential to predict progression-
free (PFS, mean, 221 days) and overall survival (OS, mean, 450 days).In patient-based 
analysis, all conventional parameters failed to predict PFS. Several textural parameters 
showed a significant capability to assess PFS. Thereby, "Grey level non uniformity" had the 
highest area under the curve (AUC, 0.93) in Receiver operating characteristics analysis 
followed by "Contrast" (AUC, 0.89). In lesion-based analysis, only "Entropy" revealed 
potential to evaluate disease progression. OS could not be assessed by any parameter 
investigated. It was concluded that tumor heterogeneity seems to be a predictor of 
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response to PRRT in patients with iodine-refractory differentiated/advanced medullary 
thyroid cancer and outperforms conventional PET parameters like standardized uptake 
value. In another study by Bundschuh et. Al., (Bundschuh et al, 2014) investigated textural 
parameters for their predictive and prognostic capability in patients with rectal cancer using 
histopathology as the gold standard. In addition, a comparison to clinical outcome was 
performed. Twenty-seven patients with rectal cancer underwent 18F-FDG PET-CT before, 2 
weeks after the start, and 4 weeks after the completion of neoadjuvant chemoradiotherapy. 
In all PET-CT scans, conventional parameters (tumor volume, diameter, maximum and 
mean standardized uptake values, and total lesion glycolysis [TLG]) and textural 
parameters (coefficient of variation [COV], skewness, and kurtosis) were determined to 
assess tumor heterogeneity. The COV showed a statistically significant capability to assess 
histopathologic response early in therapy (sensitivity, 68%; specificity, 88%) and after 
therapy (79% and 88%, respectively). Thereby, the COV had a higher area under the curve 
in receiver-operating-characteristic analysis than did any analyzed conventional parameter 
for early and late response assessment. The COV showed a statistically significant 
capability to evaluate disease progression and to predict survival, although the latter was 
not statistically significant. In our study, the predictive value of parameters and the defining 
parameters were different from that in the studies mentioned above. The differences can be 
because of different tumor type and different therapeutic agents. However, the findings of 
our study correspond to the results of all the above mentioned studies in the aspect that in 
that tumor heterogeneity was a better parameter for prediction of therapy response than the 
conventional parameters SUVmax, SUVmean, and lesion size. 
 
In the study entropy was the parameter with highest p-value and thus potential for 
best predictive capability in pre-therapy analysis for identifying high risk patients and those 
for whom therapy will be effective. Similarly, for post-therapy analysis entropy had highest 
p-value for identifying patients with high risk for disease progression and death, followed by 
intensity variation and homogeneity. 
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The changes in textural heterogeneity showed a very interesting pattern throughout 
the course of study. For the pre-therapy analysis the lesions which showed greater entropy 
and intensity variation and lesser homogeneity showed better predictive potential. Meaning 
that the more heterogeneous a tumor was better response it was showing to therapy, as 
increased entropy and intensity variation are directly proportional to the heterogeneity of a 
tumor. This particular point has been discussed in detail in the previous section of 
discussion. However, in the analysis of post therapy scan (after three therapies) it was 
observed that the patients who had decreased tumor textural heterogeneity showed a 
survival potential than those who showed persistently high textural heterogeneity. So, after 
three therapies patients with lower entropy and intensity variation and higher homogeneity 
showed better outcome and potential for survival than those showing persistently higher 
entropy and intensity variation and lower homogeneity. It could show that during the course 
of treatment PSMA therapy effectively brought some changes to the texture of tumor which 
resulted in increased homogeneity to tumor texture. There is published data analyzing the 
effects of chemo or radiation therapy on tumors at molecular and genetic level. As also 
described in introduction the origin of textural heterogeneity in tumors can be traced to 
molecular and genetic level, hence they can be good depicters of changes brought along 
by therapy at these levels.  
 
A study (Zeng et al., 2011) showed interactions between various genes and 
radiotherapy and chemotherapy.  211 patients with pancreatic cancer were recruited in a 
population-based study. Sixty-four candidate genes associated with cancer survival or 
treatment response were selected from existing publications. The main effect of genetic 
variation and gene-specific treatment interactions on overall survival were examined by 
proportional hazards regression models. In a recent study (Bravatà et al.,2018) evidence 
was given of the substantial alterations in gene expression levels and pathways after 
ionizing radiation treatment in both immortalized and primary cell cultures. Overall, the 
ionizing radiation-induced gene expression profiles and pathways appear to be cell-line 
dependent. The data suggest that some specific gene and pathway signatures seem to be 
linked to hormone receptor status. These findings show that not only radiotherapy brought 
73 
 
changes into tumor behavior at molecular level but also that these changes were very 
specific for tumor type. Hence, tumors with increased PSMA expression can behave in an 
entirely different way than other tumoral cell lines. The lesions which were more 
heterogeneous before the start of therapy in our study responded better to treatment owing 
to specific characteristics of both tumor and tracer but during the course of treatment the 
therapy gradually changed the characteristics of tumor and hence the survival potential. 
These findings are in accordance with the results obtained through numerous studies 
mentioned before which conclude that increased textural heterogeneity is a poor predictor 
to treatment response and overall survival. 
 
These findings also suggest that every tumor has a very unique and individual 
behavior and textural parameters can not only help in predicting that behavior but also can 
determine the patient outcome and disease progression. Therefore, these parameters can 
be an important part of personalized therapy. These are very important findings to 
understand the subsequent effects of a therapy on tumoral behavior. Persistent 
heterogeneity after multiple therapies and thus poor outcome can lead to the inference that 
there might be some resistant clones not responding to therapy and thus can be labeled as 
non-responders. 
 
Our study provided some good data on the role of tumor textural heterogeneity in 
predicting treatment outcome, overall survival, selection criteria for patients and to 
differentiate between actual and pseudo progression (in the case of high grade gliomas). 
Textural parameters in these ways can provide us with useful clinical information. It can 
help in identifying non-responders to treatment and can also help in distinguishing the 
patients who can respond better to a specific therapy. Textural heterogeneity parameters 
can influence the decision making in therapy planning by providing better identification of 
responders. It can serve as a basis for personalized therapy. Personalized therapy is now 
gaining a lot of importance for increasing the efficacy of treatments and modifying therapy 
options in order to provide patients with more effective treatment options. Analysis of 
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textural heterogeneity parameters can help in achieving these goals and can directly affect 
the outcome of patient which can result in significant decrease in disease burden. 
 
This study had some limitations. First, the reproducibility of tumor heterogeneity as 
assessed by PSMA PET-CT has not been much explored yet. For the assessment of this 
robustness repeated analysis of PSMA PET-CT studies will have to be performed in a short 
interval of time. For FDG-PET-CT, such a study has been performed by Tixier et al. and 
demonstrated reproducibility of textural parameters comparable to the range of 
conventional SUV (Tixier et al., 2011). They found that several textural parameters showed 
reproducibility comparable to the range of conventional SUV. Therefore, these parameters 
can be applied for therapy response assessment at least with the same confidence as 
SUV. However, this result should be validated by further studies. The analysis of 
heterogeneity can also be limited by the size of the lesion. If the lesion becomes too small, 
the analysis of differences in radiotracer uptake within the lesion does not make sense. 
Investigating small structures, e.g. lymph node metastases, may challenge the value of 
textural parameters. In our study, the smallest lesion was 8.7 cm3, which is still about 62 
voxels. A second point that needs further investigation is the influence of reconstruction 
parameters on tissue heterogeneity. PET reconstruction algorithms require smoothing of 
the raw image data which could influence assessment of tumor textural heterogeneity. PET 
images assessed in this study were reconstructed using the standard protocols for clinical 
routine at our institution. For comparison of changes in tumor heterogeneity, all images 
were acquired and reconstructed with the same set of parameters. In a study (Yan et al., 
2015), it has been shown that the impact of reconstruction settings on texture parameters is 
unclear, especially relating to time-of-flight (TOF) and point-spread function (PSF) 
modeling. Their effects on 55 texture features (TF) and 6 features based on first-order 
statistics (FOS) were investigated. Standardized uptake value (SUV) measures were also 
evaluated as peak, maximum and mean SUV. The coefficient of variation (COV) of each 
feature across different reconstructions was calculated. Results showed that Peak SUV, 
mean SUV, 18 TFs and 1 FOS were the most robust (COV≤5%). The features which 
exhibited large variation such as skewness in FOS, cluster shade and zone percentage 
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should be used with caution. The entropy in FOS, difference entropy, inverse difference 
normalized, inverse difference moment normalized, low grey-level run emphasis, high grey-
level run emphasis and low grey-level zone emphasis are the most robust features. 
Similarly, in another study (Morita et al., 2016) the purpose was to examine the effects of 
different reconstruction algorithms on the degree of heterogeneity of FDG uptake as 
assessed by texture analysis. The heterogeneity of the 18F distribution was evaluated 
according to fourteen texture features on a SUV histogram, a co-occurrence matrix 
(NGLCM), and a neighborhood gray-tone difference matrix (NGTDM). This was obtained 
using different algorithms on a phantom. In the comparison between ordered-subsets 
expectation maximization (OSEM) and time-of-flight (TOF), thirteen features, including two 
SUV histogram features, seven NGLCM features and four NGTDM features showed similar 
patterns. On the other hand, in the comparison between OSEM and point-spread function 
PSF, six features, including one SUV histogram feature, one NGLCM feature and four 
NGTDM features showed similar patterns. In the comparison between PSF and PSF+TOF, 
thirteen features, including two SUV histogram features, seven NGLCM features and four 
NGTDM features showed similar patterns. TOF correction did not influence the evaluation 
of the heterogeneity on PET images, while PSF correction affected the evaluation of 
heterogeneity. In our studies we have used the textural parameters which are robust as 
analyzed by several algorithms. 
 
Furthermore, as another drawback of this study, metabolically active tumor volumes 
were delineated manually instead of using segmentation algorithms with fixed thresholds 
and might therefore be prone to interindividual differences. However, the appropriate 
segmentation method is still widely discussed; semiautomatic methods often fail depending 
on the tumor localization (Zaidi et al., 2012; Bundschuh et al., 2012). Therefore, we 
considered manual delineation to be optimal for our study especially as we included 
metastases varying in location as well as signal-to-background ratio. Additionally, Hatt and 
colleagues (Hatt et al., 2013) could demonstrate that the predictive value of textural 
parameters is not affected by partial volume effect and is relatively independent of the 
method used to delineate the tumor volumes to be analyzed.  
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5. Abstract 
Introduction: PET-CT is emerging to be the most efficient tool for tumor diagnosis and 
therapy monitoring. Some newer techniques like analysis of tumoral textural heterogeneity 
via PET are proving to be more effective than conventional PET parameters for diagnosis, 
patient selection and treatment planning. We carried out this study to analyze the role of 
textural heterogeneity parameters in improving the specificity of PET scans. The study was 
divided in three parts. In the first part, we explored the role of textural features in FET-PET 
for early detection of pseudoprogression in high grade gliomas as timely detection of 
pseudoprogression is crucial for the management of patients with HGG. In the second part, 
the objective was to assess the predictive ability of tumor textural heterogeneity parameters 
from baseline 68Ga-PSMA PET for patient selection prior to 177Lu-PSMA therapy. This could 
prove essential for response prediction and risk stratification of patients before the start of 
therapy resulting in better treatment outcome. Purpose of the third part of study was to 
investigate the role of tumor heterogeneity in pre and post therapy 68Ga-PSMA scans for 
early response prediction and estimation of over-all survival in patients with 177Lu-PSMA 
therapy. Materials and methods: For distinction between PsP and actual tumor progress 
fourteen patients with HGG and suspected of PsP underwent FET-PET. A set of 19 
conventional and textural FET-PET features were evaluated and subjected to unsupervised 
consensus clustering and cluster stability assessment. The nearest shrunken centroids 
method was applied to determine the most relevant features underlying each cluster. The 
final diagnosis of true progression vs. PsP was based on follow-up MRI using RANO 
criteria. In the second part of study, retrospective analysis of 70 patients with mCRPC was 
performed. Five PET based textural heterogeneity parameters (COV, entropy, 
homogeneity, contrast, size variation) were determined in baseline 68Ga-PSMA scan. 
Results obtained were then compared with clinical parameters including pre and post 
therapy PSA, alkaline phosphate, bone specific alkaline phosphate levels and ECOG 
criteria. Spearman correlation was used to determine statistical dependence among 
variables. ROC analysis was performed to estimate the optimal cutoff value and AUC. In 
the third part of study, retrospective analysis of 50 patients undergoing 177Lu-PSMA therapy 
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was performed. Pre-therapy, mid-therapy and post-therapy scans were used for analysis. In 
addition to conventional parameters, 5 PET based textural heterogeneity parameters were 
determined. ROC and Kaplan-Meier analyses were used for response assessment, time to 
progression and survival. Results: For differentiation of PsP, three robust clusters were 
identified. None of the patients with PsP fell into cluster 2, which was associated with high 
values for textural FET-PET markers. Three out of 4 patients with PsP were assigned to 
cluster 3 that was largely associated with low values of textural FET PET features. In 
comparison, tumor-to-normal ratio (TNRmax) at optimal cut-off 2.1 was less predictive of 
PsP (negative predictive value 57% for detecting true progression, p=0.07 vs. 75% with 
cluster 3, p=0.04). Furthermore, patients in cluster 2 were associated with a comparably 
lower progression-free survival. In the second part of study, in bone lesions entropy showed 
a negative correlation (rs = -0.327, p = 0.006, AUC = 0.695) and homogeneity showed a 
positive correlation (rs = 0.315, p = 0.008, AUC = 0.683) with change in pre and post 
therapy PSA levels. Other parameters did not show statistically significant correlations. It 
suggested that the more heterogeneous the tumor was in PSMA expression the more 
responsive it was to PSMA therapy. For the third part of study, in bone lesions entropy, 
homogeneity and intensity variation (AUC 0.725, 0.679, 0.716 respectively) showed 
statistically significant ability to predict response prediction. Entropy showed highest 
statistically significant capability to evaluate disease progression and to predict survival. In 
pre-therapy analysis the lesions with higher textural heterogeneity showed better response 
to treatment, however after 3 therapies patients having lesions with persistently high 
textural heterogeneity showed poor prognosis and survival. Conclusions: Textural 
heterogeneity parameters helped in distinguishing PsP from actual progress thus plying an 
essential role in therapy planning and patient outcome. For 177Lu-PSMA therapy our study 
showed a potential for response prediction through one baseline Ga-68-PSMA scan only. It 
also predicted which patients could respond better to the therapy thus forming selection 
criteria for patients that can help in better treatment planning for individual patients. In 
analysis of pre and post therapy data for the third part of study, tumor heterogeneity 
analysis proved to be superior to the investigated conventional parameters, as an important 
predictive factor in determining the therapy response and overall survival of patients. 
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